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ABSTRACT
DEVELOPMENT OF A NOVEL NANOTECHNOLOGY-BASED VACCINE
ADJUVANT AND DELIVERY SYSTEM FOR SYSTEMIC AND MUCOSAL
IMMUNITY
MOHAMMED BAKKARI
2019

Many serious infections for which there are no existing vaccines, enter by a mucosal
route such as HIV, influenza, and tuberculosis, etc. Therefore, designing safe and
effective mucosal vaccines that elicit robust immune response at mucosal sites is still a
major challenge without a safe mucosal adjuvant. Previously, our laboratory had
discovered inulin acetate as a novel toll-like-receptor-4 agonist (adjuvant).
The study in this dissertation explored the application of nanoparticles prepared
with inulin acetate (InAc-NPs) as a vaccine adjuvant and delivery system for enhancing
mucosal immunity. The rationale behind selecting InAc-NPs is their proven ability to
activate strong systemic immunity along with an extensive understanding of their
mechanisms of activation.
In chapter-II, we have clearly established, through intranasal vaccinations in
mice, that InAc-NPs could generate strong systemic and mucosal antibodies (IgG1,
IgG2a, sIgA) and cytokine response that represents both humoral and cellular immunity.
InAc-NPs efficiently delivered the antigen into macrophages as well as activated them to

xiii

release inflammatory cytokines such as TNF-α, which have been attributed for robust
immune response in mice.
In chapter-III, the efficacy of InAc-NPs as a vaccine adjuvant in swine model
was established for the first time along with the safety profile in mice. InAc-NPs are
proficient in stimulation of swine PBMCs to secrete cytokines such as IL-6, IL12, and
IFN-. Importantly, InAc-NPs carrying the influenza peptide (M2e) produced higher
mucosal and systemic antibodies compared to unadjuvanted antigen in pigs. The study,
for the first time, showed InAc as a vaccine adjuvant in pigs that will have significant
implications in swine industry and human health.
In chapter-IV, InAc-NPs were explored as a delivery system to carry TLR7
agonist C-563 to its target site in the phagosomes/endosomes of antigen presenting cells.
InAc-NPs loaded with C563 provided a unique dual adjuvant and/or a delivery system for
vaccines that require robust immune response such as cancer or influenza vaccines.
In conclusion, we have demonstrated the ability of InAc-NPs as a robust vaccine
adjuvant and a delivery platform that provides strong systemic and mucosal immunity,
which will have significant implications in fighting challenging diseases such as HIV,
influenza, cancer, and tuberculosis.

1

CHAPTER-I

INTRODUCTION

2

1.1 Vaccines
In the last century, vaccines have made a significant contribution to human health and
overall global wellbeing. Vaccination has resulted in the eradication or a dramatic
reduction in the number of cases of smallpox, polio, and tetanus [2]. Each year, millions
of people of all ages worldwide are saved due to an increase in their awareness of
vaccines and immunization. In 2015 alone, 116 million infants received the diphtheriatetanus-pertussis vaccine and approximately 85% of the world's children received one
dose of measles vaccine, according to WHO [3].

A vaccine trains the immune system to recognize a specific pathogenic antigen
and exploit the generations of immunological memory for a rapid response and clearance
of the related pathogen, without causing clinical disease [4]. Vaccines support the
development of a strong immune response against infection and one shot of
immunization may last for more than a decade [5]. Therefore, apart from antibiotics, a
vaccine represents a highly efficient, life-saving technology in the history of infectious
diseases [6]. However, a huge technological gap still exists when attempting to develop a
successful vaccine against pandemic diseases, such as influenza, cancer, human
immunodeficiency virus (HIV), hepatitis C virus (HCV) and respiratory syncytial virus
(RSV). The challenges that face traditional vaccine technologies are related to their
efficacy and safety, which therefore deem them inappropriate for some age groups;
additionally, they may not be effective for all diseases [7]. Many of the currently used
vaccines contain killed or attenuated pathogens. Several vaccines, such as MMR
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(Measles, Mumps, Rubella), chicken pox, oral polio, seasonal influenzas, and yellow
fever vaccine, contain weakened pathogens. Vaccines which have killed pathogens
include Hepatitis A and inactivated polio vaccines. Despite the fact that these marketed
vaccines claim to be safe and noninfectious, they may provide only short-lived protection
or require frequent doses for further protection, which increases the risk of evoking an
infection in immune-compromised recipients [8]. Hence, many current vaccine
developments have shifted toward the use of subunit or recombinant vaccines, which
offer better safety, as well as fast and effective production. Subunit vaccines mainly
contain highly purified antigens, the part of a pathogen that produces protective
immunity. However, unlike attenuated vaccines which contain multiple target antigens,
subunit vaccines consist of a single antigenic target, thereby generating a lower immune
response against a pathogen [7]. In order to boost immunogenicity, subunit vaccines are
usually formulated with the addition of immunostimulants or adjuvants, such as
aluminum hydroxide [9].

Adjuvants boost the effectiveness of vaccines by improving and sustaining immune
responses, reducing the dose of antigen needed, and enhancing the spectrum of the
immune response. Adjuvants are usually mixed with an antigen during the production of
the vaccine formulations [10]. All vaccines contain some form of adjuvant, whether it is
exogenously added or inherently present in the vaccine. However, selecting the right
vaccine-adjuvant combination requires a clear understanding of both the protection
mechanisms of the antigen and the interaction of the adjuvant with the immune system.
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1.2 Vaccine Adjuvants

Adjuvants are substances that are added to vaccines to enhance, modulate or prolong the
immunogenicity of the vaccine’s antigen, and thereby, help to boost their protection
against the infection[11]. By increasing efficiency, adjuvants reduce the need for multiple
doses and broaden the scope of recipients, thus becoming appropriate for both elderly and
young patients. In the presence of an adjuvant, protein-based vaccines have become more
effective and have been successfully developed as human vaccines[12].

The adjuvant/immunopotentiation effect can be achieved, not only by the addition
of an adjuvant or immunopotentiator, [13] but also by modulating the context of antigen
delivery using different delivery systems, such as liposomes and emulsions (Fig. 1.1).
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Figure 1.1. Adjuvants mechanisms of action [14].

Table 1.1: Commonly reported Vaccine Adjuvants and Delivery systems
Antigen delivery systems

Immune potentiators/Adjuvants

Alum.

MPL and synthetic derivatives.

Calcium phosphate

Saponins.

Tyrosine.

Alternative bacterial component –
LPS

Liposomes.

dsRNA.

Virosomes.

MDP and derivatives.

Emulsions.

CpG oligonucleotides.

ISCOMS

Lipopeptides

Virus-like particles

Viral components – ﬂagellin etc

Microparticles/nanoparticles
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Typically, pathogens stimulate the innate immune system through their interaction
with a specific group of receptors in antigen presenting cells (APCs), called pattern
recognition receptors (PRRs). PRRs recognize highly conserved molecular motifs
associated with microbes/pathogens, called the pathogen-associated molecular patterns
(PAMPs)[12]. The PRRs include nucleotide-binding oligomerization domain (NOD)-like
receptors (NLRs), C-type lectin receptors (CLRs) and Toll-like receptors (TLRs). PRRs
can also recognize the materials released from surrounding cells due to disruptive
triggers, which are called damage-associated molecule patterns (DAMPs). In many
studies, isolated PAMPs or similar molecules have been shown to augment the immune
response when combined or conjugated with the desired antigen[6]. Thus, many new
generation vaccine adjuvants are targeted for PPR agonists or motifs [Table 1.1]. Of all
the PRRs, TLRs are gaining popularity as vaccine adjuvants due to their high efficacy.

1.3 Innate Immunity: Toll-like Receptors (TLRs)
Mammalian immunity consists of two essential subsystems, innate and adaptive
immunity, which work cooperatively to achieve comprehensive protection from
numerous pathogens and toxins. Initially, innate immunity was considered a naïve firstline defense system that provided non-specific antimicrobial activity and involvement in
the early signaling required for subsequent adaptive immune responses [15].
Nevertheless, recent studies have revealed that the innate immune system has a major
role in determining and shaping the adaptive immune response to invading pathogens.
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The downstream signaling and the recurrence of adaptive immune cells are much
predicated upon the level and nature of the preliminary signals apparent in pathogen
recognition by innate immune cells following infection and vaccination [16].
PRRs are responsible for recognizing the invading organisms and determining
whether a specific, continuous response and protection will supervene. The Toll-like
receptors (TLRs) family is one of the well-known PRRs, which are expressed on APCs,
innate immune cells (macrophages, B cells, and dendrites), and several epithelial cells
which are involved in the downstream signaling pathways of functional relevance to
immune activation and tolerance [13]. TLRs detect the highly constitutive and conserved
pathogen structures, PAMPs [14], or damage associated molecule patterns (DAMP).
Examples of PAMPs which can be recognized by TLRs include lipopolysaccharides
(LPS), lipopeptides, single-stranded RNA, double-stranded RNA, flagellin and a CpG
motif-containing DNA (Fig. 1.2).
Upon recognition of PAMPs or DAMPs by their specified TLRs, APCs produce
the inflammatory cytokines and costimulatory signals necessary for an up-regulation of
adaptive immune responses [17]. At the periphery site, dendritic cells or macrophages
capture the recognized pathogens and process them to allow a proper presentation to
adaptive immune cells, such as T-cells or B-cells. Phagocytosis of the pathogen leads to
activation and maturation of APCs, which then immigrate to nearby lymph organs to
interact with adaptive T- and B-cells [18]. B-cells can recognize the intact antigen in
soluble form, whereas the interaction of APCs with T-cells is a very sophisticated process
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using a cellular complex called Major Histocompatibility complex (MHC) on its surface
[19].

Figure 1.1: Signaling pathways of TLRs [20]
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APCs express MHC class I and class II; their role in antigen presentation depends
on the nature of the pathogens. Typically, extracellular infections (e.g. most bacterial
infections) are presented by MHC class II molecules to the T-helper (Th) cells, whereas
intracellular antigens (e.g. viral infections, tumors) are presented by MHC class I
molecules to the cytotoxic T-cells (CTLs), which can directly eliminate the infected cells
[21]. Along with antigen presentation, APCs express co-stimulatory signals, release
various cytokines to activate natural killer (NK) cells (innate immune response) and
amplify T-cell and B-cell effector functions (adaptive immune responses) [22].
Therefore, the type of MHC presentation partially influences the pathogen
clearance strategies initiated by the adaptive immunity system, whether a humeral or
cellular response. When antigens present through MHCs, several co-stimulatory
molecules are expressed and cytokines are released, simultaneously driving T-cells to
differentiate into diverse T-cell types, such as T-helper 1 (Th1) and T-helper 2 (Th2). The
helper T-cells play a significant role in directing the activities of the immune system [23].
Th1 is related to the cytotoxic activity component of T-cells. Differentiated Th1-cells
release cytokines, such as interferon (IFN)-γ, interleukin (IL)-2 and tumor necrosis factor
(TNF)-β, which help to coordinate cytotoxic T-cell (CTL) activity as a component of
cellular immune response. In contrast, the Th2-response (humoral response) stimulates
the release of antibodies, such as IgG1, IgA and IgE by B-Cells [24]. TLRs play a
critical role in communicating between the innate and adaptive immune systems.
Therefore, targeting TLRs has become of considerable interest in the development of
vaccine adjuvants in the recent past. A number of vaccine products with TLR-ligands as
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vaccine adjuvants are now marketed or in the clinical phase for human use [25] [Table
1.2].

Table 1.2: Major examples for current TLRs adjuvants formulations that clinically
tested or licensed. Adapted from reference [11, 26]
Adjuvant
Classes
Outcome
Study phase
CpG
TLR9 agonistEnhance antibodies titers against Phase III
oligonucleotides
the infectious pathogen, Th1 type
immunity and CD8 T-cell
mediated immunity in Melanoma
vaccine therapy.
Flagellin
TLR5 agonist Enhance internalization of
Phase I
flagellin linked
flagellin linked antigen, stimulate
antigen
TNF-a production and Th1 &
Th2 immunity
Polyl: C
TLR3 agonist Antibodies titer enhancement for Phase I
double standard
nasal Influenza vaccination , Th1
RNA analogues.
type immunity and CD8 T-cell
mediate immunity
AS03
TLR4 – H5N1
Improve antibodies responses
Licensed and H1N1
and cell mediated immunity.
GSK
influenza
antigens.
AS04
TLR4 (MPL) Enhance seroprotection nearly
Licensed Alum, HBV and
100 % and increase humeral and GSK
HPV
cellular immunity.
(Cervarix)
Imiquimod TLR7/8 –
Imiquimod enhanced Ag specific Phase I, II
Prostatic peptides antibodies and CD4 responses in
cancer patients.
Pam3Cys
TLR2- OspA Elicit high Ag-specific IgG
Phase II, III
Lyme
antibodies protection (90%).
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1.4 Mucosal Immunity
Mucosal membranes cover the surfaces of the gastrointestinal, respiratory, and urogenital
tracts. These membranes are the entry points for many dangerous pathogens and cause
diseases such as influenza, tuberculosis, acquired immune deficiency syndrome (AIDS),
herpes, diarrhea, and pneumonia [27]. The immune system, when challenged by a
pathogen via the mucosal route, responds by activating the systemic and/or mucosal
defense systems. A systemic response occurs via antibodies that are secreted into the
bloodstream. A mucosal defense response occurs through secretory immunoglobulin type
A (sIgA) antibodies that are secreted into the mucosal tissues[28]. Mucosal tissues are
considered a first line immunity defense, which has led to a notable focus on mucosal
vaccines in recent years. Conventional vaccines induce a poor mucosal immune response.
The more effective way to induce a mucosal immunity response is to administer the
vaccines directly to mucosal membranes. Mucosal vaccines are capable of inducing both
systemic and mucosal protection responses against pathogens [29]. Unfortunately, the
development of a mucosal vaccine has to overcome several challenges, which requires a
better understanding of mucosal immunity [30]. These challenges include poor immune
response, development of tolerance, limited antigen uptake, and safety due to the
sensitivity of the mucosal surface.
Understanding mucosal immunity must begin with the study of the epithelial
lining of mucosal membranes. This is the location of the majority of immune cells,
including APCs, lymph nodes, and other immune components [31]. The lymph nodes
form a pocket of tissue for lymphocytes in a structure called mucosal associated
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lymphoid tissues (MALT), which are located below the mucosal surface. Although the
MALT compartment function is separate from the systemic immune system, their
structures are similar. MALT is populated by different types of lymphocytes, such as
dendritic cells (DCs), and B- and T-lymphocytes. MALT has common structures that are
relevant to mucosal membrane location, such as the gut-associated lymphoid tissues
(GALT), bronchial-associated lymphoid tissues (BALT) and the nasal-associated
lymphoid tissue (NALT) [32]. GALT includes specialized structures called Peyer’s
patches, located in the small intestine. Overall, MALT structures cover approximately
80% of all immunoglobulin-producing cells in the human body [33]. MALT protects
mucosal surfaces from pathogen colonialization, prevents the harm of commensal
bacteria and elicits tolerance against consumable soluble substances. Therefore, MALT is
exposed to a large number of antigens on a daily basis. Lumina propria are considered
effector sites where sIgA antibodies are released, and where NKs and macrophages
operate against pathogens [34]. Antigens are either taken up by assimilative epithelial
cells or through specialized epithelial cells called microfold cells (M-cells). M-cells are
located in Peyer’s patches and facilitate antigen transport across the epithelium [35]. Mcells were discovered in 1974 by Owen and Jones, who revealed their underlying role by
having them sample exposed antigens (Fig.1.3). M-cells deliver dangerous antigens to
the APCs of the innate immune system, mainly through DCs, B-cells, and macrophages
[36].
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Figure 1.3. Antigen sampling at mucosal surfaces: a collaboration of epithelial cells and
dendritic cells.[37]

Distinguishing neutral antigens from pathogenic antigens in the mucosal
membrane requires keen recognition of the danger signals, such as pathogen associated
molecular patterns (PAMP) by PRRs. The recognition of pathogens in mucosal surfaces
involves the uptake of foreign substances at the epithelium by DCs or the transport
through M-cells or goblet cells to get underneath APCs for further processing and
maturation [38]. Innate immune cells at mucosal membranes express different PRRs. It is
thought that NOD1 is predominately expressed in the innate cells of lungs and intestines.
Toll-like receptor 4 (TLR4) is thought to be predominantly expressed in the respiratory
area and vaginal tract, whereas TLR7 is expressed in the human intestinal mucosa [29].

14

APCs are activated through PPRs in response to danger signals. APCs release
costimulatory molecules and present processed antigens to adaptive B- and T-cells or
they may be transported to local lymph nodes for maturation and further activation [39].
The presentation of peptide fragments through major histocompatibility complex class I
or II (MHC-I or MHC-II) molecules on the APC surface, which display the antigenic
material for homing CD 4+ or CD 8+ T-cells, depending on the type of antigen. After B
and T adaptive cells are activated, they migrate through the lymphatic system to mucosal
sites where they differentiate into effector and memory cells [40]. The activated mucosal
B-cell response to the second exposure to an antigen reacts by producing sIgA at the
mucosal membrane. sIgA is the only antibody to resist protease degradation in the
mucosal environment and survives for a long period [41]. sIgA is the dominant antibody
secreted in the mucosal fluids of the intestine, internasal mucosa, and saliva. It is a dimer
of two monomeric IgA molecules that are covalently linked by a joining chain (J chain)
molecule. The molecules bond together with a component molecule produced by mucosal
epithelial cells, which help with the resistance of protease cleavages [42]. The protective
role of sIgA at the mucosal surfaces gives it the ability to neutralize pathogens and inhibit
them from penetrating through and adhering to the mucosa. This protection role is
demonstrated by its ability to decrease the attachment of influenza virus and inhibit virus
internalization [43]. sIgA also suppresses the proliferation, colonization, and entrance of
pathogens across the epithelium [44].
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1.5 Mucosal Vaccines
The main goals of mucosal immunization are to generate an adaptive response at the site
of pathogen invasion and to prevent infections or diseases by activating humoral mucosal
defense (sIgA) and systemic humoral and cellular responses. The local immune response
depends on the vaccine's route of administration. Intranasal vaccination leads to a strong
mucosal response in the respiratory tract [36]. Interestingly, some mucosal vaccines, such
as Kennel Cough vaccine, can generate a response within 48 to 72 hrs.; this indicates a
possible use for fast control of endemic infections[45]. After mucosal membrane
exposure to the antigen and the activation of memory T-cells, a portion of the memory Tcells migrates to mucosal effector non-lymphoid tissues. These cell populations, called
resident memory T-cells, produce a fast effector function and provide high protection
against infection when re-exposure occurs [46]. For mucosal therapeutic vaccination
against local lung tumors, local delivery of the antigen has been shown to induce local
effector cytotoxic T-lymphocytes (CTLs) by local DCs through upregulation of different
T-cell subtypes (CD49a, CD103, and CD8þ) in the lung parenchyma [47]. Only the
intranasal route was able to trigger local DCs and cause infiltration of the tumor by CD8,
thus causing tumor regression. The common mucosal response, which is signified by the
immune response in multiple mucosal tissues, is one of the highlighted advantages of
mucosal vaccines. Mucosal immunization routes, such as oral, rectal, and intranasal, can
encourage general mucosal immune responses at distant effector sites. In fact, respiratory
immunizations induce antibody responses in a broad variety of tissues, including saliva
and the urogenital tract (Fig. 1.4).
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In contrast, oral immunization induced a more restricted mucosal response, which
may be due to their restricted homing receptor profile. [43]. In addition to these
advantages, mucosal vaccination has also improved the cost, safety, and physical and
psychological comfort of vaccine administration. However, despite the advanced features
that mucosal vaccination can add to modern vaccines, only a few licensed mucosal
vaccines are available now, due to the challenges of generating a strong immune
activation by this route.
Notably, most of the licensed mucosal vaccines are composed of weakened
viruses or whole pathogen materials. Recently, subunit vaccines have emerged as an
alternative, potential approach. Subunit antigens include soluble or recombinant proteins,
which are weak immunogens. Therefore, the development of subunit mucosal vaccines
has evolved to ensure a suitable delivery or adjuvant system, aiming to augment the
immune response, reduce the toxicity risk and improve the cost over conventional
vaccines [48] [Table 1.3]. The route of administration, along with the appropriate
adjuvant and delivery system, is targeted for better antigen delivery and greater
stimulation of APCs. Large particle forms of antigens or synthesized nanoparticles have
been reported to possess an immune-stimulating feature, as they have pathogen-like
forms and can be immunogenic by themselves or with the incorporation of PAMPS [49].
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Figure 1.4. Antibody response in mucosal immune system [50].
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Table 1.3: Licensed Mucosal Vaccine
Infections.

Antigens.

Route of
Administration.

S. Typhi

Live-attenuated S.

Oral

Poliovirus.

Live-attenuated poliovirus.

Oral

influenza

Live-attenuated
influenzas,
A/H1N1, A/H3N3.

Nasal.

Rotavirus.

Live reassortant rotavirus, G1,
G2, G3.
Live- attenuated human virus
G1p.
Killed whole-cell O1, O139,
and recombinant CTB subunit.

Oral

Cholera

Oral

1.6 Strategies to Induce Mucosal Immune Responses
1.6.1

Local Administration

The stimulation of APCs at the mucosal sites, including oral, internasal, or intratracheal
sites, promote T-cell homing at the same site. The oral and nasal routes are the most
suitable to trigger the cellular machinery which initiates IgA and induces an adaptive
effector response in mucosal tissues. For example, the oral vaccines against pathogens
such as S. Typhi and Poliovirus have been available for decades and have generated
efficient and adequate immune protection for individuals [51]. Another example is the
immunization of children using the intranasal formulation of the influenza vaccine,
FluMist, which results in greater protective immunity compared to the intramuscular
route [52]. The aerosol administration of live-attuned Edmonston-Zagreb measles vaccine
generates high serum antibodies and mucosal IgA titers when compared to the
subcutaneous route [53]. Intranasal vaccination with an influenza virus, in combination
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with the outer membrane of Neisseria meningitis, resulted in a significant increase in
serum and nasal wash antibodies with no observed toxicity [33].

1.6.2

Mucosal Adjuvants

Although most known parenteral vaccine adjuvants use augmented systemic antibody
cellular immune response, most of them are not as effective as mucosal adjuvants [6].
Continuous efforts are underway to develop adjuvants for subunit vaccines that trigger
cellular events which involve IgA secretion or induction of adaptive effector cells at
mucosal sites [54]. Despite the fact that local delivery of mucosal vaccines has a better
potential to induce mucosal immunity due to their low immunogenicity, immune
enhancers are a necessary part of the mucosal vaccines. This can be achieved through an
integrated adjuvant system where the system provides improved retention at the site of
administration, better antigen delivery, as well as immune activation through specific
PRRs [55]. Delivering vaccines through a particulate system offers efficient delivery and
protection of the antigen cargo in a harsh environment. Bioengineered cationic
nanoparticles showed increased adherence to the epithelial cells at the nasal mucosa; this
format was shown to be significantly effective in boosting immune responses [31]. The
fabricated biocompatible particles and biodegradable polymer are more suited to uptake
by Peyer’s patches or APCs at the mucosal sites. Furthermore, some of the nonmicrobial
products (e.g., oil emulsions, liposomes or nanoparticles) act as mucosal adjuvants by
delivering antigens or by causing mucosal damage or disruptive stress leading to the
release of DAMPs at the site of vaccination. DAMPs adjuvants, such as hydroxypropyl–
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B-cyclodextrin, work in the nasal mucosae and cause epithelial damage at high
concentrations, release the DNA of hosting cells and induce Th1 [48]. For example, the
EndocrineTm adjuvant also works by inducing cell death and by releasing RNA at local
mucosal cell sites after nasal administration, which suggests DAMPs stimulation
pathways [56]. Exogenous mucosal adjuvants are not limited to DAMPs molecules, but
also include a wide range of discovered PAMPs, which have been extensively studied as
systemic and mucosal vaccine adjuvants. A number of these molecules have successfully
made it to the market. Examples of PAMPs include bacterial toxins, CpG motifs,
monophosphoryl lipid A, saponins and live vectors.

Bacterial toxins and their derivatives
Nontoxic derivatives of the cholera toxin (CT) and Escherichia coli (LT) have been
intensively applied as adjuvants to induce mucosal immunity. They showed the capability
to induce strong systemic and mucosal antibody immune responses and evoke cellular
immunity in vaccinated models [57]. As a mucosal adjuvant, CT derivatives have
demonstrated strong responses through intranasal administration; however, in the murine
model, toxicity in the olfactory nerve was observed. Therefore, the development of
mutant LT, in the form of LT-k3, was used as a safe and potent adjuvant for intranasal
co-administration of recombinant measles virus nucleoprotein [58]. Despite the lower
toxicity of mutant forms of CT and LT, the toxicity of others toxins as mucosal
adjuvants, remain uncertain and safety is still is a major concern [59].
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Monophosphoryl lipid-A (MPLA)
MPLA is a detoxified derivative of LPS from Salmonella Minnesota R595, Gramnegative bacterium. It is a TLR4 agonist that proved to induce mucosal immunity when
administrated by mucosal routes. MPLA has been introduced into various formulations
and marketed in combination with Alum (AS04) in the commercial prophylactic vaccine,
Cervarix [48]. To induce mucosal immunity, intravaginal administration of MPLA and
saponin formulations was shown to enhance systemic and mucosal immunity in an HIV
vaccine study with macaques [60]. Furthermore, MPLA induces a strong systemic
response after intranasal vaccination of mice, with the addition of a cationic liposomehyaluronic acid hybrid nanoparticle and the antigen Yersinia pestis [61]. In addition, a
comparison study was done with MPLA mucosal adjuvant and the two potent mucosal
adjuvants, CpG and the B subunit of Escherichia coli (LTB), for use as a pulmonary
vaccination with Mycobacterium tuberculosis. The results reported that MPLA generated
a Th-17 type response by increasing IL-17A levels in the lungs and spleen [39].
CpG motifs
The oligodeoxynucleotide (OND), containing unmethylated cytosine-phosphate-guanine
motifs (CpG), is a well-known TLR9 agonist, which stimulates CD4+ Th1 and CD8+ CTL
responses and induces protective immune responses such as those triggered by bacterial
DNA. CpG has been used intranasally with anthrax lethal toxin and produced promising
data as a mucosal adjuvant. It induced high levels of Ag-specific mucosal sIgA and
serum IgG2a antibodies against anthrax lethal toxin [28]. Moreover, CpG was tested in a
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pneumococcal vaccination. Nasal administration of a plasmid encoding the cDNA of the
Flt3 ligand and CpG adjuvant improved mucosal protection [62]. Additionally, mucosal
administration of CpG adjuvants is believed to be associated with less toxicity. In in vivo
studies, CpG-ODN demonstrated a potent Th1 type immune response. The administration
of CpG ODN via the lung route for treatment of allergies has tested safe in primates and
humans [63].

Saponins
Saponins are glycosides containing a hydrophobic backbone of a triterpenoid structure
linked to a carbohydrate chain [64]. Saponins were found to induce strong immune
responses against antigens, including cytotoxic T-cell responses [65]. The saponin
component, Quil A, has the ability to interact with the membrane cholesterol, disrupt the
intact barrier and form pores which increase the antigen uptake to induce strong
immunity. When it is administrated orally in the form of a lipophilic immune-stimulating
complex (ISCOMs), the saponin adjuvant Quil A reported a significant systemic immune
response, including Th1, Th2 and protective secretory IgA antibodies [66]. Another study
focused on a semi-synthetic derivative of the saponin adjuvant, GPI-0100, used as a
mucosal adjuvant for influenza subunit vaccines with different mucosal routes. Strong
mucosal antibody response in the respiratory tract was observed with intrapulmonary and
intranasal vaccination. In addition to the protective mucosal response, GPI-0100 elicited
strong systemic immune responses [67].
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Live vectors
Bacterial carrier systems, such as live bacteria vectors and lactic acid bacteria systems,
have grown rapidly as DNA vaccine adjuvants through mucosal routes, including
intranasal, oral, or intravaginal routes [68]. For example, vectors derived from salmonella
have been used as vaccine cargo to deliver antigens and to elicit mucosal and systemic
levels of protective antigens in appropriate lymphoid inductive sites. Most of the live
vector systems have been reported to induce both antibody and T helper responses
against recombinant antigens [69]. Additionally, these vectors have also been utilized to
develop therapeutic cancer vaccines that deliver tumor-associated molecules, such as
cancer antigens, RNAs or DNA.
1.7 Mucosal Vaccine Development: Challenges
Despite continuous efforts in the development of mucosal vaccines, only a few have been
approved for use in the market, in contrast to the many registered injectable vaccines. The
key challenge has been the low immunogenicity of antigens when delivered to mucosal
surfaces due to their poor accessibility to local immune cells under the nasal epithelial
barrier (Fig. 1.3). The natural protection barrier created by mucus production at the
mucosal membrane and its transport through cilia, which are meant to keep pathogens
away from the epithelium, limits antigen retention and transportation across the
epithelium. Moreover, the high molecular weights of the antigens hamper their transport
across the epithelium to reach the lamina propria where the majority of the local immune
cells reside. Antigen degradation at the mucosal surface also contributes to poor antigen
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delivery. This is a concerning problem for unprotected protein, particularly in the
gastrointestinal tract. Further difficulties appear with the tolerance nature of mucosal
immune response surfaces.
To address those problems, advanced vaccine delivery systems that have the
potential for immune activation are required. As mentioned before, the rational design for
a vaccine system should have safe and efficient adjuvants, as well as an appropriate
delivery system to improve antigen protection, increase antigen uptake and enhance the
immune response to the antigen.

1.8 Next-Generation Mucosal vaccine Strategies
1.8.1 Nano-Vaccine Delivery Systems
Drug delivery systems which are based on polymeric or lipid particles are part of many
licensed pharmaceutical products. However, very few licensed vaccines are based on
particulate systems [70]. Polymeric particulate systems have several advantages for use in
vaccine delivery, which include their ability to be recognized and taken up by APCs due
to their particulate nature, their versatility to modulate the particle size and shape, and
their charge to suit the target in the immune system [71]. The size range of various
reported vaccine delivery systems is described in Figure 1.5.
It has been suggested that smaller polymeric particles produce higher antibody
titers than larger particles, due to the higher amount of antigen adsorption. One of the
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well-known vaccines nano-particulate delivery systems is PLGA polymer-based
nanoparticles. For example, PLGA particles encapsulating ovalbumin and CpG ODN
were found to have better uptake by DCs and good up-regulation of CD86 and MHC
class I molecules on BMDCs, when compared to particles >300nm [70]. Additionally,
polymers can also be used as self-adjuvating delivery systems, therefore increasing the
resident time and delivering efficient antigens or epitopes to immune cells at mucosal
membrane [72]. Thus, the polymeric nanoparticle became particularly attractive because
it was found to stimulate better antigen uptake by APCs [72]. In addition to providing
antigen protection by facilitating antigen transport to immune cells, the key factor in
nanoparticulate delivery systems is boosting immune response. Similarly, researchers are
showing a growing interest in using natural polymers based on polysaccharide to prepare
nanoparticle adjuvants. Particles have been prepared from polymer-like chitosan,
pullulan, and inulin [31]. For instance, chitosan-based nanoparticles have gained much
popularity for vaccine delivery due to their high safety profile, biocompatibility, and ease
of modulating the system [51]. Several studies used chitosan nanoparticles with various
vaccines, including DNA and HBV vaccines. Another example of natural polymer-based
particles is the inulin-based nanoparticles, which are known as potent adjuvants due to
their activation of the complement system via the alternative pathway [52]. AdvaxTM is
a commercial nanoparticle adjuvant derived from inulin, which has been shown to
enhance the immune response in influenzas and hepatitis B vaccines [42].
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Figure 1.5. The size range of common vaccine delivery systems.

Other advantages of nanoparticle systems are their capability to be modulated into a
mucoadhesive particle and to enhance the uptake of antigens by nasal epithelial cells
and/or M-cells. In addition, targeting M-cells may improve the uptake and transport of
antigens to the sub-epithelial region of the NALT and subsequent secondary lymphoid
organs. Apart from lymphatic distribution, many studies have supported the utility of
nanoscale-modified material to transport and facilitate the move molecules or antigens
through the gastrointestinal tract or respiratory route.
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1.8.2 Targeted Adjuvants: TLR Agonists
The most striking feature of next generation vaccine delivery components is their
immunogenicity and their ability to attract APCs[73]. Throughout the examples
mentioned earlier, the recent advances in successful mucosal adjuvant candidates were
oriented toward using APC receptor ligands or improving delivery systems. Thus, the
current trends are to achieve better immune responses based on mimicking pathogens by
delivering vaccines through the particulate system using immune-attracting properties.
TLR targeting is an activation feature that can be fabricated into the particulate system
with micro- or nano-sized particles, representing viral and bacterial shapes, as described
below.
1.9 TLRs in Mucosal Immunity

TLRs are expressed by many cell types in the mucosal tracts, including epithelial cells,
monocytes, macrophages, and dendritic cells [74]. TLRs (e.g. TLR2, TLR3, TLR4, and
TLR7/8) play an essential role in maintaining the integrity of the epithelial cells and
controlling the mucosal immune system [75]. TLRs influence the initiation, maintenance,
and progression of inflammatory diseases. TLR receptors also perform a strong role in
innate immune signaling by maintaining the right balance of the microbiota in the
mucosal compartment [76]. The expressions of TLRs in the mucosal system vary,
influenced by diseases, bacteria or dysregulation of the immune responses [74]. The
nature of the adaptive immune responses at the mucosal membrane also shows unique
features, including preferential secretion of IgA and a large population of T-helper 17
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(Th17) cells, a CD4+ T-cells subset (characterized by the production of highly
inflammatory cytokine), and interleukin-17. Although Th17 is not TLR dependent, TLR
signaling involves either induction of mucosal protection, IgA responses, or an adaptive
immune response which influences Th1 and Th2 responses [77]. Several potent TLR
ligands have been studied as adjuvants for mucosal immunizations in different models
and through different routes of mucosal administration. Examples of those adjuvants
include FSL-1 (TLR2/6), poly I∶C (TLR3), MPLA (TLR4), CpG-B (TLR9), Pam3CSK4
(TLR1/2), and R848 (TLR7/8) [78].

1.10 Inulin Acetate is a Polymer-based TLR4 Agonist
Inulin is a natural fructan classified as a dietary fiber, in which an unbranched chain of
fructose moieties is linked to terminal glucose [79]. Inulin was introduced to the
pharmaceutical industries as a stabilizer for drug or protein formulations, peptide-based
drugs and vaccine formulations [80-83]. Inulin can exist in both water-soluble and waterinsoluble forms, depending on the procedures used to precipitate it. The insoluble forms
of inulin (gama and delta) have been shown to activate the immune system through
alternate complement pathways [79].
Recently, our group has shown that hydrophobic acetylated inulin (inulin acetate,
InAc) stimulates the innate immune system through the activation of TLR4 on APCs.
However, the parent compound inulin failed to activate TLR4 [84]. Furthermore, InAc
did not activate the alternate complement pathway, similar to insoluble inulin [84]. The
TLR4 agonistic activity of these polymers was established in multiple immune cells
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(microglials, dendritic cells, and PBMCs) by various genetic and pharmacological
approaches.
The investigational study by our team has shown that acetylated inulin (inulin acetate)
particles activate the innate immune system, thus acting as a potent vaccine adjuvant
[84]. Inulin Acetate is synthesized as a polymeric immune active compound with TLR4
agonistic activity. It has the ability to stimulate multiple immune cells, such as in microglial,
dendritic, peripheral blood mononuclear and exclusive TLR4 expressed cell epithelial cells
[84].

1.11 Pathogenic-Mimicking Delivery System prepared using InAc as a Biomaterial
By using InAc as an immune-active polymer, our laboratory has rationally engineered a
“Pathogen-Mimicking Vaccine Delivery System” (PMVDS) that could potentially
encapsulate multiple antigens [85]. The uniqueness of our PMVDS is that it is both an
efficient vaccine delivery system, similar to nanoparticles, and a vaccine adjuvant due to
its ability to activate TLR4. The polymers and PMVDS particles were thoroughly
characterized by a myriad of physicochemical techniques. The effect of the size of the
particles and the dose of an antigen and adjuvant on immune activation was studied in
mice. The safety of PMVDS was assessed using cytotoxicity, skin histochemistry and invivo imaging techniques. The robustness of PMVDS in preventing and treating diseases
was investigated on influenza and melanoma mouse models.
The first study to examine the InAc particulate-based PMVDS reported the ability
of such a system to target antigen-presenting cells, such as dendritic cells. [85]. PMVDS
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offered a polymeric vaccine adjuvant delivery system that activated the innate immune
system via TLR4 and produced a high humoral and cellular response. A nanoparticle model
using InAc as the polymer to target immune cells also showed advanced results, compared
to PLGA nanoparticles. It showed efficient encapsulation of the antigen and potent
activation of multiple immune cells, including DCs and primary swine and human cells
[86]. The uniqueness of the PMVDS technology is its combination as both vaccine
adjuvant and delivery system. InAc particles were able to enhance immune response when
injected along with an antigen (Ova) [85]. However, encapsulation of the antigen in InAc
particles in the form of PMVDS advanced the humoral response significantly and
generated significant cytotoxic T-cell activity against cancer cells. The advanced feature
of PMVDS over other adjuvant systems is attributed to the utilities of the polymeric
particulate system as a delivery system. Thereby, it offers the advantage of delivering both
an antigen and an adjuvant to the same cell, which has been shown to be critical in
determining the adaptive immune response [87] (Fig. 1.6).
In addition to the vaccine delivery system and the protection of the antigen,
PMVDS could be used to deliver other interested molecules to immune cells, such as
small molecule-based vaccine adjuvants (chapter IV). One of the advantages of PMVDS
technology is the affordability of the raw materials and the ease of preparation, which is
essential when translating lab discoveries into field/clinical applications.
Being a particulate delivery system, PMVDS offers several future opportunities,
such as tunable physical properties, the prospect of encapsulation, the controlled delivery
of multiple antigens, and simultaneous incorporation of other immune-stimulatory factors
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or PAMPs. There is further potential for InAc particles to target M-cells for mucosal
immunity. M-cells represent a critical portal for mucosal drug and vaccine delivery.
Several studies showed that delivery through M-cells could be achieved using particulate
delivery vehicles, such as PLGA or liposomes. The delivery through M-cells can vary,
depending on the properties of the delivery system [88].

Figure 1.6. PMVDS adjuvant and vaccine delivery systems [85].

Based on previous findings, we hypothesize that PMVDS could be an important
candidate for mucosal vaccine delivery due to its modulating particulate features,
targeting properties and immune potentiation nature.
In this dissertation, the ability of InAc nanoparticles to stimulate both systemic
and mucosal immunity after intranasal administration was investigated in mice and pigs
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using model antigen ovalbumin and influenza viral subunit antigen M2e peptide
(Chapter-II& III). Further more, InAc-NPs were utilized to deliver small molecular-based
TLR7 agonist C-563 along with the antigen as a multifunctional vaccine delivery system
(Chapter IV) to activate robust systemic and mucosal immunity.
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Chapter-II
Novel Immune Active Nanoparticles as Intranasal
Vaccine Delivery System for Inducing Systemic and
Mucosal Immunity.
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2.1. Introduction
Nasal vaccination often elicits mucosal immune responses in the respiratory tract, which
is important in preventing numerous respiratory infections such as influenza and bacterial
pneumonia. In contrast to injectable vaccines, intranasal vaccinations have critical ability
to provide antibody-mediated protection at the respiratory mucosal site of pathogen
entry[89]. In addition, they exhibit common protection at various distal mucosal tissues
such as intestinal and urogenital tracts. Therefore, intranasal vaccination has been an
attractive preventive strategy for not only respiratory infections but also genitourinary
infections[54]. Despite these advantages, producing a protective immunity against several
mucosal diseases is still a challenge that often requires large doses. This may be due to
the instability of antigen at the mucosal surface or lack of suitable mucosal vaccine
adjuvant[90].
The effective strategies are utilizing live attenuated organisms for nasal
vaccination, and a good example is a seasonal influenza virus vaccine (FluMist®).
However, FluMist is limited to only individuals with strong immunity (2–49 years of age),
leaving the most susceptible populations such as infants and the elderly [91]. Moreover, as
a live attenuated vaccine, FluMist has the high unpredictability of protection against
different strains of the same pathogen and has a potential risk of adverse side effects. These
challenges shift the focus on developing subunit intranasal vaccines[48]. However, subunit
antigens are not highly immunogenic and often require a potent vaccine adjuvant and
special delivery system to boost the immune stimulation. The current vaccine adjuvant
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discovery research is mainly focused on pathogen recognition receptor (PRRs) present on
professional antigens presenting cells (APCs) as targets, such as a Toll-Like receptor
(TLRs) or Nod-Like Receptors (NLRs). TLR ligands mimic pathogen-associated
molecular patterns (PAMPs) and initiate signaling for a strong adaptive immune response
[26]. Of several TLRs discovered, TLR4 has been a major target of vaccine researchers for
both systemic and mucosal immunity. The first FDA-approved TLR4-based adjuvant is
AS04 in human papillomavirus vaccine, Cervarix. It contains alum and MPLA
(Monophosphorylate lipid-A), a TLR4 ligand as active ingredients [54],[92]. In addition to
immune adjuvants, several particulate vaccine delivery systems have been reported based
on encapsulating immune stimulant and subunit antigen in the form of nanoparticles or
microparticles for improved immune stimulation [92, 93]. Particulate delivery system
provides several advantages including, increased antigen stability by protecting it from
degradation from both exogenous and endogenous factors, and improved immune
stimulation by increasing the uptake of antigen by APCs. Thereby, particulate vaccines
greatly enhance the efficacy of the intranasally administered vaccines [94],[95].
In a search for novel vaccine adjuvants, our laboratory previously reported the
discovery of a polymeric toll-like receptor-4 (TLR4) agonist, inulin acetate (InAc) that
activates TLR4 on several APCs including, microglial, dendritic, and peripheral blood
mononuclear cells from various species [84-86]. InAc was synthesized from a plant
polysaccharide inulin[85]. Furthermore, we have prepared both nanoparticle- and
microparticle-based pathogen-mimicking vaccine delivery systems (PMVDS) using
bioactive InAc as a polymer to improve antigen delivery to APCs and induce a higher
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immune response [84, 85]. A particulate-PMVDs stimulated both humoral and cellular
immune responses against the encapsulated antigen when delivered through subcutaneous
or intradermal routes. However, through parentral routes tested, InAc-based vaccines
failed to stimulate mucosal immunity.
In this chapter, we evaluated the ability of InAc-based nano-vaccine delivery system
(InAc-NPs) as a versatile platform for mucosal vaccination through intranasal delivery.
InAc-NPs with around 250 nm in diameter were prepared with ovalbumin as an antigen.
InAc-NPs as a delivery system activated mouse macrophage cells to release
inflammatory cytokines, however, failed to stimulate macrophages from mice deficient in
TLR4 receptors, which further affirms the TLR4 agonistic properties of the delivery
system. When administered intranasally to mice, immune-active InAc-NPs produced very
strong systemic (IgG1 and IgG2a) and mucosal antibody response (sIgA) against the
encapsulated antigen. Strong secretory-IgA (sIgA) antibody titers were recorded in
various mucosal tissues such as lungs, intestine and nasal-associated lymphoid tissue
(NALTs). InAc-NPs provide a unique immune-active delivery system as a platform
technology for various mucosal vaccines.
2.2. Materials and Methods
2.2.1. Materials
Inulin was purchased from MP Biomedicals Solon, OH, USA. The poly (lactic-coglycolic acid) (PLGA) was purchased from Sigma-Aldrich, St Louis, MO, USA.
Monophosphoryl lipid A (MPLA) and Lipopolysaccharide-RS (LPS-RS) was purchased
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from Invivogen, San Diego, CA, USA. Macrophage cells (NR-9456 & NR-9458) were
obtained through BEI Resources, ATCC, Manassas, VA, USA. Mouse macrophages were
cultured in RPMI glucose medium (Thermofisher Scientific, USA), supplemented with
antibiotics (penicillin/streptomycin) and 10% fetal bovine serum (FBS). MPLA and
endotoxin free ovalbumin (Ova) was purchased from Invivogen, Sandiego, CA, USA. All
other chemicals were purchased from Fisher Scientific, Pittsburgh, PA, USA.

2.2.2. Synthesis of inulin acetate and preparation of nanoparticles
Inulin acetate (InAc) was synthesized by acetylating hydroxyl groups of inulin using
acetic anhydride and characterized by Fourier transform infrared (FTIR) and proton
NMR spectroscopy as described previously [84, 85]. Inulin acetate nanoparticles (InAcNPs) were prepared with and without the antigen ovalbumin by double (w/o/w) emulsion
followed by solvent evaporation technique as described in earlier manuscript[86]. Briefly,
the primary emulsion was prepared with an aqueous phase of 10 mM phosphate buffer
(PB, pH7.4) containing 2% (w/v) Pluronic F-68 solution as a surfactant, with/without
Ova. The oil phase was prepared by dissolving InAc (100 mg) in dichloromethane
(DCM). The aqueous solution was added drop by drop to the polymer solution to form a
primary (w/o) emulsion. Then, the formed emulsion was added drop-wise into water
containing 0.5% (w/v) polyvinyl alcohol. The mixture was sonicated with an
ultrasonicator probe for 5 min, 10 seconds on - 1 second off cycle, using a Q500
Sonicator (Qsonica, CT). To evaporate DCM, the final emulsion was stirred for 12 hrs.,
and the precipitated particles were collected via centrifugation at 50,000xg for 30 min at
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4℃ and lyophilized. PLGA nanoparticles (PLGA-NPs) were prepared by a similar
method by using PLGA instead of InAc[84]. The nanoparticles prepared without antigen
are called blank-nanoparticles.
2.2.3.

Size and zeta potential

Size and zeta potential of nanoparticles (NPs) were measured by a dynamic light
scattering (DLS) technique (Malvern Zeta-Sizer, Malvern Ltd, MA, USA). The NPs were
re-suspended in a filter-sterilized citrate buffer (10 mM, pH 7.4), and diluted using filter
sterilized water before recording particle size and z-potential.

2.2.4.

Scanning electron microscopy (SEM)

The shape and size of InAc-NPs were evaluated using a scanning electron microscope
(SEM Model S-3400N, Hitachi, Japan). For the preparation of samples, lyophilized
powder free from cryoprotectant was mounted on a metal holder using conductive
double-sided tape. The particles were sputter coated with a 10-nm gold layer before
analysis. The micrographs were captured at a beam voltage of 5 kV, and 50,000×g
magnifications were used for imaging, with a working distance of 5-15 mm and a spot
size of three. The ImageJ software was used to measure the average diameter of the
particles, with the average diameter representing at least 100 particles.

2.2.5.

Determination of Ova loading

The amount of antigen encapsulated into the nanoparticles was calculated as described
elsewhere[84]. A measured amount of Ova containing InAc-NPs was added to acetone
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and incubated at 37 °C for 4 hrs. As the acetone dissolved the InAc polymers, the Ova
was precipitated, which was collected by centrifuging at 10,000 xg for 30 min. The
collected pellet was dissolved in 1% sodium dodecyl sulfate (SDS) solution. The Ova in
SDS solution was quantified by a Pierce™ Bicinchoninic acid (BCA) Protein Assay Kit
(Thermo Fisher Scientific Inc., Waltham, MA, USA), according to manufacturer’s
instructions. The Ova loading (n = 3-4) was reported as μg of Ova present per mg of
InAc-NPs (w/w).

2.2.6.

Determination of endotoxin levels

The endotoxin levels in the final preparation were determined using the ToxinSensor™
Chromogenic LAL Endotoxin Assay Kit from GenScript (Piscataway, NJ), following the
manufacturer's instructions. All formulations used in this study have a low detection limit
of endotoxins as per the United States Pharmacopeia for parenteral administration [96].

2.2.7.

In-vitro antigen release studies

To study the release kinetics of antigen from InAc-NPs, Ova loaded InAc-NPs (10 mg)
were dispersed in 10 ml of 10 mM PB (pH 7.4) and stirred at 100 RPM at 37 °C using an
orbital shaker. At predetermined time intervals, an aliquot of 500 μl was withdrawn and
centrifuged at 20,000g to collect the supernatant. The amount of Ova released in the
supernatant was determined by the Micro-BCA method after filtering through a 0.2 μm
filter.
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2.2.8. TLR4 activation assay
The effect of InAc-NPs on activating TLR4 was studied using mouse macrophages (Ø)
from wild-type and TLR4 knock out mice[15]. Triplicate wells containing macrophages
were incubated with different concentrations of blank InAc-NPs without antigen (50, 100
and 250 μg/ml) or PLGA-NPs (250 μg/ml) for 48 hrs. A well-known TLR4 agonist
MPLA (2 μg/ml) was used as a positive control. The activation of macrophages was
quantified by determining the levels of TNF-α in the culture supernatants using TNF-α
ELISA Ready-SET-Go Kit (e-Bioscience, San Diego, CA). The concentration of TNF-α
was calculated based on a standard curve generated with mouse recombinant TNF-α. The
TNF-α levels from untreated cells were considered as a background[97].

2.2.9.

Cellular uptake of InAc-NPs in the macrophage

The cellular internalization or uptake of InAc-NPs loaded with fluorescently labeled Ova
(FITC-Ova) was studied using mouse macrophage cells. Macrophages were cultured on
glass coverslips for 24 hrs. for attachment. Subsequently, the cells were treated for 1 hr
with the following agents: no treatment (only media), FITC-Ova as a solution (25 µg/ml)
and FITC-Ova delivered through InAc-NPs. The cells were washed with cold 50 mM
phosphate buffered saline, pH 7.4 (PBS) for 3 times followed by fixing with 4% w/v
paraformaldehyde in PBS. Cellular uptake of FITC-Ova was observed under a
fluorescence microscope.
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2.2.10. Mice Immunization
The experiments involved using animals were reviewed and approved by the Institutional
Animal Care and Use Committee (IACUC) of the South Dakota State University. Male
BALB/C mice (n = 4-5 per group, 6–8 weeks old) purchased from The Jackson
Laboratory (Bar Harbor, ME) were used for all experiments. Immunizations were
performed under light isoflurane anesthesia. Mice were immunized intranasally (i.n) with
10-15 μl of vaccine formulations per nostril using a micropipette. The antigen Ova (20µg
/ dose) was administered as a solution in saline or through PLGA-NPs or InAc-NPs (~2
mg of NPs) as a delivery system. Primary immunization (day 1) was followed by two
booster doses with 2-weeks apart. Blood was collected on days 14, 28, and 42. The serum
was separated using Microtainer serum separator (BD Biosciences, San Jose, CA) and
stored at -20 °C until further analysis. On day 42, lung fluid (20-30 μl) was collected from
euthanized mice after carefully administrating 50 μl PBS with protease inhibitors into the
lungs through the trachea. The intestinal washes were collected after the entire small
intestines were surgically removed from euthanized mice and perfused with 10 ml PBS
with protease inhibitors. The supernatants from the intestinal washes were collected after
centrifugation at 5000 xg at 4°C. The lung and intestinal washes were stored at −20°C
until further use.
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2.2.11. Nasopharynx-associated lymphoid tissue ex-vivo culture
On day 42 after the primary immunization, the Nasopharynx-associated lymphoid tissues
(NALT) palates were surgically removed from each mouse under aseptic conditions.
Each individual palate was intensively washed with a complete medium consisting of
RPMI-1640 supplemented with 10% fetal bovine serum, 100 μg/ ml streptomycin, 100
UI/ ml penicillin, and 50 μg/ ml gentamicin. The plates were cultured for 36 hrs. in 48well plates (Becton Dickinson, Franklin Lakes, NJ) containing 500 μl of the fresh
complete medium at 37°C with 5% CO2. Supernatants were collected from each NALT
culture, centrifuged to remove fragments and stored at −20°C until further analysis [98].

1. NALTs were
surgically removed
from euthanized mice.

2. After proper washing,
NALTs were incubated in
medium at 37 ºC, for 36
hrs.

3. Sample were collected by
centrifuging supernatants at 5000 xg,
sample were analyzed for sIgA using
indirectt ELISA.

Figure 2.1. Ex-vivo culture for Nasal Associated Lymphatic Tissues.

2.2.12. Splenocyte proliferation assay and Cytokine analysis: ex-vivo
Single cell suspensions of the splenocytes were prepared from the spleens of immunized
mice, as described previously [85]. The splenocytes (1 × 106 cells/well) were seeded in
triplicate into a 96-well plate, either with Ova (100 μg/ml) or with concanavalin A (5
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μg/ml; Con A) as a mitogen. After 3 days of incubation at 37°C (5% CO2, 95%
humidity), the plates were centrifuged for 10 min at 4000 xg to pellet the cells, and 200 μl
of supernatant was collected for the analysis of secreted cytokines. Cell proliferation was
assessed in the same plates by adding 50 μl of 3-(4, 5-dimethylthiazol-2-yl-2, 5diphenyltetrazolium bromide) (MTT) assay as described in earlier manuscripts [85].
Stimulation indices (SI) were calculated by dividing the mean OD540 of Con A, or Ova
treated cells by the mean OD540 of untreated cells containing the only medium.

2.2.13. Cytokine analysis
Sandwich-ELISA assay was used to measure the cytokines in the supernatants of the
splenocytes culture. The assay was performed using a Mouse Th1/Th2 ELISA ReadySET-Go Kit (e-Bioscience, San Diego, CA) as per the kit instructions[99].
2.2.14. Statistical analysis
Results were expressed as mean ± standard deviation (SD). The data were analyzed using
Instant Graph Pad software (CA), and the significant differences in the mean were tested
by Student's t-test or two-way ANOVA followed by Bonferroni's or Dunnett's post-hoc
multiple comparison tests for statistical significance. P<0.05 was considered a
statistically significant difference unless specified under figure legends.
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2.3. Results and Discussion
A strong immune activation at the mucosal surface serves as a first line of defense against
the entry of mucosal pathogens. A vast majority of human vaccines are administered
parenterally, which often fail to provide protection at the mucosal surface. Due to the
paucity in the availability of efficient technologies, there are only very few mucosal
vaccines available in the market. Therefore, the development of a safe and effective
mucosal vaccine adjuvant/delivery system has been the priority for non-replicating or
subunit-based vaccines. In a previous study, our laboratory had demonstrated that a novel
immune active vaccine delivery system (microparticles) prepared with a bioactive
polymer, InAc significantly increased the antibody and cell-mediated immune response
to an intradermal and suncutaneously injected vaccine[84, 85]. In this report, InAc-NPsbased nanovaccine delivery system is established for its ability to elicit strong mucosal
and systemic antibody response after intranasal vaccination. The activation of TLR4 by
InAc-NPs was further confirmed using wild-type and TLR4-knockout macrophage cells.
The improved antigen delivery and immunostimulatory properties (TLR4 agonist) of
InAc-NPs contributed to strong antibody response produced by InAc-NPs-based delivery
system.

2.3.1.

Physicochemical characterization of InAc-NPs-based vaccine delivery system

As described previously, InAc polymer was prepared by acetylating the hydroxyl
functional groups of fructose/glucose subunits of inulin by using acetic anhydride under
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inert gas [85]. The formation of InAc and the batch-to-batch consistency were assessed
by 1H-NMR spectroscopy and Fourier transform infrared (FTIR) spectroscopy [84]. In
the previous manuscript, the role of the presence of an acetyl function groups and the
high hydrophobicity of InAc in activating TLRs have been discussed [85]. Using InAc as
a major polymer, nanoparticles were prepared by encapsulating ovalbumin as an antigen
using a double-emulsion solvent-evaporation method. The InAc-NPs were characterized
by their size, shape, charge, antigen loading, and presence/absence of endotoxins. The
size of NPs was around 245 nm in average diameter with a slightly negative charge (0.62) as determined by dynamic light scattering (DLS) (Fig.2.2A-B). Further, scanning
electron microscopy (SEM) images revealed InAc-NPs as spherical particles with an
average diameter of 253 ± 5.2 nm (Fig. 2.2C). The nanoscale features of InAc particles
aimed to enhance the intimate interaction with epithelia at nasal mucosa, facilitate the
uptake of the antigen by APCs and improve the delivery of the antigen to the lymphoid
tissue for enhancing immune stimulation [100]. The preceding research has shown that
nanoparticles are preferentially phagocytosed by APCs and elicit stronger cytokine
release compared to microparticles [101, 102] [102]. In this context, the delivery system
performs a major role in augmenting nasal mucosal immunity. Nanoparticles have been
explored as nasal or pulmonary vaccine carriers mainly due to their potential to diffuse
through the mucosa, their avoidance of degradation, and their ability to co-deliver both
adjuvants and antigens[103]. In addition, due to their size range, NPs are trapped in the
mucin matrix, which further promotes their interaction with the nasal epithelium [54,
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104]. Taken together, we hypothesize the InAc-NPs will be suitable as an intranasal
vaccine delivery system.

A.

B.

C.
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Figure 2.2. Characterization of inulin acetate based nanoparticles used for intranasal
vaccine delivery. (A) Particle size distribution measured using DLS as percent intensity.
(B) Surface charge (ζ-potential) distribution. (C) Scanning electron microscopy showing
inulin acetate nanoparticles with spherical morphology.

Encapsulating proteins into a hydrophobic matrix such as InAc or PLGA is a
challenging task. The double emulsion-based method provided better loading of antigen
(µg of protein/mg of final formulation) in InAc particles than nanoprecipitation as shown
previously [85]. Around 22 ± 4.57 µg and 20 ± 8.13 of ovalbumin was loaded for every
milligram of InAc-NPs and PLGA-NPs, respectively. The antigen, Ova was released
from InAc-NPs in a sustained pattern over 16 days, after around 20 % of the encapsulated
antigen was released immediately within 30 min of incubation (Burst release) [Fig.2.3].
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This dual release pattern of antigen is considered advantageous for vaccines [105] as it

% Cumulative Release of
Ova

provides fast and continuous antigen stimulation[106].
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Figure 2.3. In-vitro release kinetics of Ova from InAc-NPs. InAc-NPs (1 mg/ml)
were dispersed in 0.1 M PBS, pH 7.4 at ~100 RPM. Ova concentration in the
supernatant solution at different time points was measured by using BCA assay (n=3).

Table 2.1: Characterization of InAc-NPs and PLGA-NPs

2.3.2.

Parameters
Size

InAc-NPs
245 ± 5.49 nm

PLGA-NPs
250 ± 2.14 nm

Loading

22 ± 4.57

20 ± 8.13

Zeta-potential

-0.62

- 2.82

InAc-NPs activate macrophages via TLR4 stimulation

To evaluate InAc-NPs stimulation of macrophage to overcome the tolerance state at the
nasal mucosal surface, an in-vitro cytokines release study was conducted with murine
macrophages. The mouse macrophages significantly released TNF-α, a potent cytokine,
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when treated with InAc-NPs or with a known TLR4 agonist monophosphoryl lipid-A
(MPLA) [Fig.2.4A]. In contrast, at the same concentration of InAc-NPs, PLGA-NPs
(inert polymer) failed to stimulate mouse macrophages [Fig. 2.4B]. However, the
activation and the secretion of TNF-α by macrophages in response to InAc-NPs was
abrogated when the cells were pre-treated with LPS-RS a TLR4 antagonist or
macrophages from the TLR4 (-/-) mice were used. The observations from the above
pharmacological and genetic methods conclude that the InAc-NPs based delivery system
(without any antigen) activates APCs (macrophages) through the stimulation of TLR4 on
their surface. However, the role of other TLRs such as TLR2 in InAc-dependent
activation of other types of APCs in an intact animal cannot be ruled out. Because of the
high expression of TLRs, including TLR4 on mucosal surfaces, their activation has a
tight and dynamic influence on regulating pathogen invasions and elimination. Our
previous studies demonstrated the immune stimulation properties of InAc on dendritic
cell and microglia [84, 107], which led us to examine its effect on macrophage activation
in this manuscript to include the gamut of APCs.
As an antigen presenting cell with highly phagocytic capability, macrophages play
a key role in bacterial recognition and elimination at nasal mucosal sites[108]. The
macrophages present in the upper respiratory tract along with other lymphocytes mobilize
to the nasal mucosa when responding to antigen stimuli [6]. Despite their abundance in
mucosal surfaces, macrophages in the steady state lack the ability to induce
proinflammatory cytokines and work to maintain the mucosal hemostasis from an
excessive immune response.

Moreover, macrophage plays a key role in producing

49

regulatory T cells and induces tolerance[108]. Stimulating macrophages with appropriate
PRR ligand is critical in driving the protective immune response. The observation that InAc
particles (TLR4 ligand) activate macrophages and various other types APCs further
supports its design for intranasal vaccine delivery system [85].
2.3.3. InAc-NPs were efficiently recognized and internalized by APCs
An ideal feature of a vaccine delivery system is its ability to target immune cells and
deliver an adequate antigen to trigger an immune response. In addition to activating
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Figure 2.4. TLR4 selective activation of InAc-NPs. Macrophages from wild-type mice (Ø WT)
and TLR knockout mice (Ø TLR4 -/-) were activated for 48 h with LPS (1 µg/ml), MPLA (2.5 µg/ml)
or blank-NPs prepared with InAC or PLGA (250 µg/ml). The activation was assessed by measuring
the concentration of TNF-α in the culture supernatant after 48 hrs. To inhibit TLR4 (panel A), TLR4
antagonist; LPS-RS (60 ng/ml) was added to the cells one hour prior to their activation. One-way
ANOVA followed by Dunnett's post-hoc multiple comparison tests indicates the significant values
of p ≤0.001 between the following groups: Panel A: PLGA vs InAc; InAc vs InAc+LPS-RS; PLGA
vs PLGA+LPS-RS, Pane B: treatments of Ø WT cells vs respective treatments of Ø TLR4 (-/-)
cells.
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APCs, the ability of InAc-NPs in delivering the antigen to macrophages was tested using
fluorescently labeled antigen. The NPs were prepared with InAc or PLGA as polymers
(Table 2.1) and FITC-ovalbumin (20:100) as an antigen. InAc-NPs were more efficient
than PLGA-NPs in delivering antigen to macrophages [Fig. 2.5]. These results are in
accordance with our previous observation that InAc-microparticles (1.428 µm in average
diameter) delivered significantly high antigen to dendritic cells[85]. Many current studies
of particulate vaccine delivery systems are designed to enhance cellular uptake with an
emphasis on particle fabrications, physiochemical characterizations, particle geometries
or the use of conjugated ligands [109] [71, 110]. Indeed, nanoparticle morphology, size
and surface charge are known to influence nanoparticle biological activity. In most
approaches, however, the chosen particulate system is a vehicle prepared with inert
materials such as PLGA or chitosan [71].
Despite having similar physicochemical properties (size, charge, and hydrophobicity) [Fig.
2.2], InAc-NPs demonstrated higher antigen delivery than PLGA-NPs. This further
emphasizes the role of TLR4 interaction in particle/vaccine recognition. In conclusion,
InAc particles have proven as an efficient antigen delivery system[84].
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PLGA-NPs

InAc-NPs

Figure 2.5. Internalization of InAc-NPs by Macrophages. Macrophage cells were
incubated for 1 h at 37 ºC with antigen (FITC-Ova) delivered using InAc-NPs or
PLGA-NPs. After incubation, cells were extensively washed, fixed in 4% (w/v)
paraformaldehyde, and observed under a fluorescent microscope. The nucleus was
stained with DAPI. The red scale bar represents 10 µm.

2.3.4.

InAc-NPs generate strong serum antibody titers in mice

Male BALB/C mice were immunized with InAc-NPs loaded with Ova (20 μg per dose)
thrice with 2-week intervals between doses. The immune response generated by the
InAc-NPs was compared to PLGA-NPs or PBS as antigen delivery systems. InAc-NPs as
a delivery system consistently produced higher antibody titers than PLGA-NPs after
primary and booster immunizations [Fig. 2.6]. After 2nd booster, InAc-NPs produced very
strong serum IgG1 antibody titers (226,115) compared to PLGA (3500) or PBS (2600) as
a delivery vehicle (p<0.001 compared to PLGA group). Similarly, the IgG2a titers were
also robust with InAc-NPs (100,653) compared to PLGA-NPs (5247) or PBS (1564) as a
delivery system. InAc-NPs stimulated ~65-fold and 19-fold higher serum IgG1 and

52

IgG2a titers, respectively as compared to PLGA-NPs as a delivery system. The data
further signifies the importance of the adjuvant properties InAc-NPs [Fig. 2.4] in addition
to their ability as a delivery system [Fig. 2.5] in generating strong antibody-response.
Previously, intradermal or subcutaneous immunization with InAc-particles
generated a very high serum IgG1 and IgG2a levels after only one booster injection.
Nevertheless, intranasal vaccination with InAc-NPs exhibited similar IgG1 and IgG2
titers only after the second booster dose, indicating that three doses may be required to
achieve the full effect. Despite producing robust serum humoral response with a smaller
number of doses, InAc-particles previously failed to produce detectable levels of mucosal
antibodies (IgA) with parenteral routes [85, 86]. However, in this manuscript, the
intranasal route was selected for its ease of accessibility, presence of high density of APC
cells, and importantly, for their ability to produce both systemic and mucosal
immunity[93] [94]. Similar to parenteral immunizations, InAc-NPs produced signals for
the activation of both humoral and cell-mediated immune responses as indicated by high
IgG1 and IgG2a antibody titers, which is further established with the type of cytokines
released [Fig.2.7]
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Figure 2.6: Serum OVA-specific IgG-1 & IgG2a titers. Mice (n = 4-5 per group) were
administrated intranasal with Ova (20 µg) alone or loaded in InAc nanoparticles (250
µg) or PLGA on days 1, 14 and 28. Sera were collected at 2 weeks after the primary,
2nd and 3rd immunizations for analysis of antibody titers using indirect ELISA. The
titer is the common end serum dilution at which the absorbance is more than average
absorbance plus two standard deviations of the PBS control. * Indicates that the results
are statistically significant at p < 0.05 as compared to PLGA group using one wayANOVA followed by Bonferroni's multiple comparison test.

The cytokine response was assessed using ex-vivo cultures of splenocytes
prepared from immunized mice [Fig. 2.7] three weeks after the second booster dose. In
an ex-vivo culture, the splenocytes were challenged with Ova, and the amount of secreted
cytokines representing Th1 (IL-2 and IFN-γ) and Th2 (IL-4 and IL-10) -type immune
responses were quantified in the culture medium. [Fig. 2.7A&B]. The splenocytes
collected from the mice immunized with InAc-NPs produced significantly higher levels
of both Th1- and Th2-type cytokines as compared to splenocytes from the mice
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immunized with PLGA-NPs or PBS as a vehicle (at p <0.01; Fig. 2.7). Besides, the
splenocytes from mice vaccinated with InAc-NPs showed a high-level proliferative
response to the antigen challenge when compared to splenocytes originated from the mice
vaccinated with Ova in PBS or in PLGA-NPs [Fig.2.8], which is an indirect indication of
a strong memory response. Similar polarization pattern was observed previously with
InAc particles using intradermal/subcutaneous routes. The activated cell-mediated
immunity was strong enough to significantly reduce or prevent tumor progression and
metastasis [85]. Taken together, the first proof-of-concept study in mice indicates that
InAc-NPs could stimulate strong systemic antibody response even after intranasal
immunization.
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Figure 2.7. The release of cellular (A) and humoral (B) cytokines in an exvivo challenge of splenocytes. Splenocytes were prepared from mice
immunized with ovalbumin in PBS (OVA) or loaded in In-Ac-NPs or PLGANPs and cultured for 72 hrs. in the presence of Ova (100 µg/ml). After 72 hrs.,
the concentration of cytokines in the culture supernatant was measured using
sandwich-ELISA. * Indicates results are statistically significant as compared to
PLGA-Ova immunized group at P < 0.001 using student t-test.
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Figure 2.8 Splenocyte proliferative responses to Ova and Con A. Splenocytes
were prepared from mice immunized with Ova alone, Ova loaded inulin acetate
nanoparticles or PLGA, and cultured for 72 hrs. in the presence of Con A (2.5
µg/ml) or Ova (100 µg/ml) or RPMI. Splenocyte proliferation was measured by
the MTT assay and shown as a stimulation index (SI). SI = the absorbance value
for treated cultures divided by the absorbance value for non-stimulated cultures.
* Indicates results are statistically significant as compared to Ova immunized
group in the same mitogen treated group (P < 0.001) using student t-test.

2.3.5. InAc-NPs boost Ova-specific mucosal IgA titers in mice
The major goal of this study is to generate strong immune responses both systemic
(humoral & cellular) and mucosal responses at lung and nasal sites, the primary sites of
several respiratory infections. Therefore, we have used three mucosal sites to quantify the
mucosal immune response as Ova specific sIgA titers: bronchial alveolar lavage fluid
(Lung washes); intestinal fluids and NALT cultures. Protection at the mucosal surface is
often correlated with secretory immunoglobulin-A (sIgA) antibodies which, along with
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other innate defense mechanisms, protect from attacking pathogens[56]. The prime
inductive site for mucosal immunity in the nasopharyngeal tract in rodents is the nasalassociated lymphoid tissue (NALT) [98]. Several studies have reported that NALT works
similar to gut-associated tissue to stimulate the common mucosal immune system [104].
Murine NALT may be a functional analog to human tonsils. The bronchial alveolar
lavage fluid and the intestinal secretions were used to determine the common mucosal
responses at distinct sites. The IgA titers secreted into the culture medium were
significantly higher from an ex-vivo cultured NALT tissue collected from the mice
immunized with InAc-NPs as a delivery system compared tissue from the mice
immunized with PBS or PLGA-NPs as vehicles [Fig. 2.1, Fig. 2.9]. The titers of NALT
from the mice immunized with InAc-NPs have higher sIgA titers (15885), compared to
NALT tissues from other groups (>30-fold). It is generally accepted that mucosal
immunity produced after nasal vaccination is not restricted to the upper respiratory tract,
as sIgA antibodies can also be detected in other mucosal secretions due to the complex
interaction of immune components from various mucosal tissues. Mucosal immunity,
mostly nasopharyngeal immunity, constitutes the major component of the immunological
humoral and cell-arbitrated responses in the lower and upper respiratory. Provoking the
antibodies protection in pulmonary surfaces lead to better eradication and protection of
respiratory infections[91]. In this regard, InAc-NPs showed higher levels of secretory
IgA antibody in the lung secretions two weeks after 2nd booster immunization (Avg. titers
11,008 ± 1677).
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Furthermore, sIgA was highly elevated in intestines of InAc-NPs immunized mice
(Fig. 2.9). The immune response in remote organs suggests that InAc-NPs was able to
evoke common mucosal immunity in mice, which is an important element of pathogens
clearance mechanism for broader protection [111]. Nasal immunization has been proved
to reflect distance mucosal responses at different effector mucosal sites, such as in saliva
and gastrointestinal tract [112]. Although common mucosal responses have almost
exclusively been reported for S-IgA antibody responses, it is expected that T cells can
also be provoked at distance sites [113]. Mucosal immunity is first line protection against
mucosal transmitted pathogens such as influenza.

Figure 2.9. OVA-specific sIgA-Titers. Mice (n = 4-5 per group) were administrated
intranasal with Ova (20 µg) alone or loaded in InAc nanoparticle (250 µg) on days 1,
14 and 28. NALTs were ex-vivo cultured after 2 weeks after 3rd immunizations, Lung
and intestines wash were performed at the endpoint. IgA analysis of antibody titers
using indirect ELISA. * indicates that the results are statistically significant at p <
0.05 as compared to PLGA group using one way-ANOVA followed by Bonferroni's
multiple comparison test.
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Several strategies have been reported including directly conjugating TLR ligands to
protein antigens or co-encapsulating immunostimulatory agents and proteins hydrophobic
polymeric particles. They have been proven to induce effective immunity as a nasal
vaccine antigen delivery system by mimicking the structure and immunological
processing of actual pathogens. However, InAc-NPs is a unique system that polymeric
delivery vehicle and immunopotentiator in one go, that allow more versatility and
modularity in design vaccines adjuvant and delivery system that suit the needs. InAcNPS produced strong humoral and systemic immune responses including mucosal
immunity against the encapsulated antigen when administered intranasally, which
confirm complete cross-protection against lethal viruses attacks[114]. Humoral response
in the mucosal tissue is critical to prevent the entry of the respiratory pathogens such as
influenza. The entry site of respiratory viruses are not limited to the respiratory mucosal
lining, but infection can occur in other mucosal surfaces. Therefore the production of
humoral response at different mucosal sites offers a great advantage in preventing
communicable diseases [115].

60

2.4. Conclusions
Overall, this first-time proof-of-concept study showed a novel mucosal vaccine delivery
system prepared with InAc as a biomaterial to stimulate both mucosal and systemic
immune response. The multidisciplinary features of this the technology is oriented on
using immune-active polymers to prepare the nanoparticles delivery system that mimics
naturally occurring pathogens in both size and immune activation. InAc-NPs has been
consistently reported to activate both humoral and cellular immune responses. The InAc
based vaccine delivery technology offers a versatile platform for delivering nasal
mucosal vaccinations against several viral and bacterial pathogens.
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Chapter-III:
Development of a Novel Mucosal Vaccine Adjuvant and
Delivery System for Influenza.
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3.1. Introduction
As one of the most prevalent respiratory diseases, influenza is responsible for substantial
mortality and morbidity worldwide causing upwards of 500,000 deaths each year (WHO,
2014). Influenza epidemics cost billions of dollars in healthcare services [116] [117].
The pathogenesis of influenza infection is mediated by a subset of RNA viruses within
the orthomyxoviridae family [118]. Immunization currently proves to be the most
efficient method of preventing influenza [119]. Commercially available vaccines are
primarily based on inactivated influenza viruses [120]. Influenza vaccines in research are
usually based on a whole inactivated or dead virus, protein subunits, split vaccines, and
virosomes [121]. Of these type different types of antigens, subunit vaccines are the most
commonly researched on account of their acceptable safety profile [122].
Influenza subunit vaccines are based on immunogenic proteins or peptides
derived from its viral structure [Fig. 3.1] [123]. These
include haemagglutinin protein (HA), a transmembrane
glycoprotein present on the surface of the virus, and a
peptide from the extracellular domain of influenza
Matrix 2 protein (M2e), a component of the viral
membrane[124]. Although subunit vaccines are deemed
safe, they are poorly immunogenic [125, 126]. Subunit

Figure 3.1. The cartoon
structure of Influenza virus
depicting surface HA, NA
and transdermal M2 proteins.

vaccines yield a moderate humoral (Th2-type) response
and fail to induce clinically relevant cellular immunity (Th1-type) including the
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generation of CD8+ cytotoxic T lymphocytes (CTL) against the virus [127]. However, to
attain complete elimination and prevention of influenza infection, activation of both
cellular and humoral immune responses is required [128-131]. The induction of potent
cellular and humoral immunity by subunit antigens can be achieved by the incorporation
of a potent vaccine adjuvant in the formulation (Chapter-I; Table 1.2). Several adjuvants
have been evaluated for influenza vaccines [118, 132]; however, their clinical utility is
limited either due to their high toxicity or their inability to induce both cellular and
humoral immunity [133-135]. These necessitate an urgent need for the development of
safe and potent vaccine adjuvants that elicit both humoral and cellular immunity [136].
Previously, our laboratory has investigated the ability of antigen-loaded Inulin
Acetate (InAc) microparticles as a vaccine adjuvant (TLR4 agonist) and delivery system
to induce complete immune response (cellular and humoral) against the influenza subunit
antigens, HA and M2e [1]. The results in mice demonstrated significant capabilities of
InAc microparticles to protect from H1N1-influenza virus infection. The immune
responses against the virus were evaluated via antibody titers in the serum, hemagglutinin
inhibition, virus neutralizing antibody titers, and secretion of Th1-type and Th2-type
cytokines [Fig. 3.1, Fig. 3.2]. Taken together, a pathogen-mimicking vaccine delivery
system prepared with a TLR4 agonist (InAc) as material with influenza subunit antigens
provided both humoral and cellular immunity. The above-unpublished study is performed
in mice using the subcutaneous route with InAc-microparticles.
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Figure 3.2. HA and M2e specific IgG-total antibody titers in immunized mice serum. Mice
(n = 4-5 per group) were injected subcutaneously with unadjuvanted HA (10 µg) or HA
loaded in InAc microparticles, unadjuvanted M2e (10 µg) or M2e loaded in InAc
microparticles on days 1 and 21 as primary and booster doses, respectively. The data
represents mean ± standard deviation (n=4-5). (adapted from [1])
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Figure 3.3. Cytokine response of splenocytes prepared from the immunized mice when
challenged with the respective antigen. Splenocytes from the mice immunized with InAc
microparticles loaded with HA or M2e secreted very high levels of cytokines representing
both Th1 and Th2 type immune responses. (adapted from [1])
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To this end, this current study investigated the ability of Inulin Acetate (InAc)
nanoparticles as a delivery system to induce a complete immune response against the
influenza subunit antigen (M2e) in a swine model. The long-term goal of the project is to
generate a universal influenza vaccine that applies to both human uses and for the swine
industry. This study is different from the previous investigations from our laboratory in
three aspects: a) the use of swine model, b) comparing the intranasal vs. subcutaneous
routes, and c) use of nanoparticles instead of microparticles. The rationale for the
proposed changes is described below. Swine model is more clinically relevant for
influenza than mouse model because of the conserved immunological components
between pigs and human both in terms of structure and function. Also, the clinical
manifestation of the disease symptoms are similar between pigs and humans, and
importantly, the swine influenza virus can be transmittable to humans suggesting
overlapping infectious mechanisms[114, 137]. Furthermore, the study in swine not only
addresses a serious influenza threat to food safety and human/farmer health but also
directly relevant to the productivity of today's swine farms improving the economics of
the farmers [138].
The intranasal route was selected to test whether InAc-particles produce mucosal
immunity in larger animal species (swine) similar to previous observation mice (ChapterII). It is important for a new novel vaccine candidate to undergo preclinical testing in two
animal models (one rodent and one non-rodent) before advancing to clinical phase [139].
However, in adjuvant research, the success of an adjuvant in one animal species cannot
be extended to another species until proven. Therefore, it is necessary to investigate in
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pigs separately. Previously, Kumar et al. have shown that InAc-microparticles produce a
depot at the injection site. InAc-NPs were selected over microparticles in this study due
to their potential ability to be cleared from the injection site because the formation of a
depot at the injection site or injection site lesions adversely affect patient compliance in
humans and meat quality in the swine industry.
The results from this study demonstrated that InAc-NPs prepared with M2e as an
antigen are around 300 nm in size, and the antigen was released in a sustained manner.
Importantly, InAc-NPs based M2e vaccine generated a strongly systemic and mucosal
humoral immune response when administrated intranasally or subcutaneously in pigs.
The data for the first time indicates the ability of InAc-NPs as a platform technology for
vaccine delivery for pigs.

3.2. Materials and Methods
3.2.1. Materials and Animals
The M2e peptide (MSLLTEVETPTRNEWECRCSDSSD) was purchased from
GenScript USA Inc. (Piscataway, NJ). Inulin, MP Biomedicals™ (Cat:198971) and all
other chemicals were purchased from Fisher Scientific (Pittsburgh, PA, USA). Goat antiporcine IgG -HRP conjugated secondary antibodies (Cat:6050-05) were purchased from
Southern Biotech (Birmingham, Alabama, USA). Goat anti-porcine IgA secondary
antibodies (A100-102P) were purchased from Bethyl laboratories, (Montgomery, TX).
Piglets (Yorkshire) purchase from Commercial Farm Herds (Midwest Swine Research,
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Minnesota). Pluronic 127 purchase from Thermo fisher scientific. Intranasal mucosal
atomization devices (MAD 300) were purchased from Teleflex, NC, USA.
3.2.2 Vaccine formulation: InAc-NPs with M2e as antigens
Antigen (M2e) loading into InAc-NPs was achieved by double (w/o/w) emulsion solvent
evaporation technique as described in Chapter-II with minor modifications. M2e antigen
(2.5 mg) was incorporated in the aqueous phase and added dropwise to the organic phase
containing for 100 mg of InAc during the first emulsification step. For the preparation of
InAc-NPs loaded with a near-IR dye carbocyanine-DiOC18, the dye was added to the
organic phase along with the polymer. The lyophilized InAc-NPs containing the antigen
or the dye were kept at 4 ºC before administration.

2.3. Measurement of antigen loading of InAc nanoparticles
The amount of peptide (M2e) encapsulated in InAc nanoparticles was determined by
using high-performance liquid chromatography (HPLC) as described previously[1]. The
M2e peptide was extracted by dispersing 10 mg of InAc-NPs in 500 μl of acetone,
followed by vortexing, and centrifugation at 14,000 xg for 15 min at 40C. InAc dissolved
in acetone, whereas the peptide precipitated. The peptide in the pellet was collected and
dissolved in 200 µl of 1 % sodium dodecyl sulfate (SDS) solution. The amount of
peptide present in the SDS solution was quantified using reverse phase HPLC with a C18
column (5 μm, 250 mm × 4.6 mm) AGILENT™. The mobile phase consisted of buffer A
(0.05% TFA and 2% acetonitrile in water) and buffer B (0.05% TFA in acetonitrile-water
(90:10, v/v) and the flow rate (0.2 ml/min). A linear gradient was performed by
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increasing the amount of buffer-B from the initial 20% to 50% [140]. The concentration
of peptide in the SDS solution was further confirmed using micro-BCA assay as
described in Chapter-II.
3.2.4. Activation of swine peripheral blood mononuclear cell (PBMCs)
Preparation and activation of PBMCs: Peripheral blood (~10 ml) was collected from
three-month-old pigs using heparinized tubes (BD Vacutainer, Franklin Lakes, NJ) and
the swine PBMCs were prepared as described previously using percoll gradient
centrifugation [84]. For the activation, the PBMCs (1×106 cells/well of a 6-well plate) in
triplicate were incubated for 12 hrs. at 37°C with 5% CO2 before treating with 200 µg/ml
of nanoparticles prepared with PLGA or InAc as polymers for 24 hrs. After the treatment,
the PBMCs were collected by centrifugation (1000 x g for 15 min) for RNA isolation.
cDNA synthesis and gene expression analysis: The total RNA from PBMCs was
extracted using the RNeasy mini kit. (Qiagen, Valencia, CA). The RNA was analyzed using
Nanodrop ND-1000 and 1% agarose gel electrophoresis. All RNA samples showed the
A260/A280 ratio around 2.00 while 1% agarose gel electrophoresis showed two distinct
bands as 28S and 18S. The RNA was converted to cDNA using the First-Strand cDNA
Synthesis kit (Thermo Scientific, Waltham, MA) and used as templates in the following
real-time polymerase chain reactions (RT-PCR) using SYBR green dye [84, 86].
Ribosomal protein large subunit 4 (RPL4) gene was used as an internal control.
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The forward primers used were:
IL6-AGATGCCAAAGCTGATGC;

TNF--GGGGTCCTTGGGTTTGGATT

IL12-AATCCTCAACCACTCCCAA;

RPL4-GGCGTAAAGCTGCTACCCTC

The reverse primers include :
IL6-ACAAGACCGGTGGTGATTCTCA; TNF-- TTGGAACCCAAGCTTCCCTG
IL12-GGCAACTCTCATTCGTGGCT

RPL4-GGATCTCTGGGCTTTTCAAGATT.

The RT-PCR conditions include initial heating at 95 ºC for 10 mins, followed by
45 cycles of 95 ºC for 15 sec and 60 ºC for 40 sec. The relative gene expression of IL-6
with internal control RPL4 was calculated. The fold change in gene expression is
represented. All PCRs were performed in triplicates. All PCRs were performed in
triplicates [85, 86].

3.2.5. Safety of InAc-NPs
3.2.5.1. In-vitro cytotoxicity: The cytotoxicity of InAc-NPs was investigated by
quantifying the viability of murine dendritic cells (DC2.4 cells) using (3-(4,5Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT assay). Brieﬂy, DC2.4
cells (5000/well in 96-well plate) were treated with InAc-NPs at concentrations of 0 to
500 μg/ml for 48 h. Subsequently, the cells were treated with the MTT solution (0.5
mg/ml; 4 hrs.) followed by dissolving the tetrazolium crystals using DMSO (150 µl/well;
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1 hr.). The absorbance was then measured at 570 nm and 650 nm [141]. The cell viability
was compared with the untreated cells.
3.2.5.2. Skin toxicity: The skin toxicity of InAc-NPs or InAc-microparticles (2 mg) or
Complete Freund's Adjuvant (CFA) at the injection site was evaluated by assessing the
gross structural damage 21 days after the subcutaneous (s.c.) injection in male BALB/C
mice using hematoxylin and eosin (H&E) staining.
3.2.5.3. Injection-site clearance and safety of InAc-NPs: Eight-week-old BALB/C
mice were injected into the footpad subcutaneously with one milligram of InAc-NPs
loaded with carbocyanine-DiOC18. The retention time of InAc-NPs at the injection site
was determined by imaging with Bruker-Xtreme in-vivo imager at excitation/emission
wavelengths of 750/780 nm [86].
3.2.6. Immunization study
Four weeks old piglets (n=5 per group) purchased from (Midwest Research Swine,
Gibbon, MN) were immunized subcutaneously (s.c.) and intranasally on day 1 and 21 as
primary and booster doses, respectively. Treatment groups consisted of M2e in saline or
InAc-M2e in saline (25 µg antigen per dose). Sera were collected two weeks after prime
and booster for analysis of M2e-specific total IgG titers by indirect ELISA as previously
described in chapter-II. ELISA plates (Fisher thermo-scientific) were coated with M2e (1
µg/well) in 50 mM carbonate buffer (pH 9.6). Results are expressed as serum IgG titers.
Bronchoalveolar fluids (BALFs) were collected from animals after necropsy (3 weeks
after 2nd booster) by introducing 50 ml of DMEM medium containing antibiotics (100
U/ml penicillin and 0.1 mg/ml streptomycin) into the lung of each pig, massaged gently
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and recollected. BALFs were further centrifuged at 2000 xg for 10 min. All supernatants
were stored at -20 C until analysis.
3.3. Results and Discussion
3.3.1. Physicochemical analysis of antigen-loaded InAc nanoparticles
The InAc particles with M2e antigen were around 315 nm in average diameter. Around
4.03 μg of M2e peptide was loaded inside a milligram of InAC-NPs (Table 3.1).

Table 3.1. Physicochemical Characterization of M2e loaded InAc nanoparticles.
Particle Size
Zeta-Potential
Polydispersity index
Loading of the antigen ( M2e peptide) (µg/mg)

315 ± 0.54
-0.6 ± 0.18
0.38
4.03 ± 0.62

▪ Data represent the mean ± standard deviation (n=3). Loading is defined as µg of antigen per
mg of InAc nanoparticles.

3.3.2. Safety and clearance of InAc-NPs from the injection site
Previously, it has been shown that microparticles prepared with InAc as the polymer
formed a depot at the injection site (unpublished data). Due to the nanoscale size of the
InAc-NPs, they are hypothesized to be cleared from the injection site by the lymphatic
system without forming a depot[142]. In swine/meat industry, lesions or having a vaccine
depot at the injection site are not acceptable. Therefore, it was important to investigate
the safety and clearance of InAc-NPs from the injection site in mice before advancing to
swine immunization.
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Multiple approaches were used to assess the safety of InAc-NPs. In-vitro
cytotoxicity studies indicate that InAc-NPs did not significantly alter the viability of
mouse dendritic cells (DCs) up to a concentration of 500 μg/ml [Fig. 3.4A]. In mice
studies, injecting 2 mg of InAc-NPs did not show any depot formation or tissue damage
at the injection site as observed through histochemistry sections (H&E staining) of the
skin at the site of injection. However, InAc microparticles and CFA showed a depot
formation at the injection site with infiltrated immune cells. Furthermore, CFA caused
distinct tissue damage at the site of injection [Fig.3.4B]. As hypothesized, InAc-NPs were
cleared from the injection site within 36 hrs of injection as shown by the fluorescence
images of the mice after injecting near-IR dye loaded InAc-NPs (Fig. 3.4C), which
further endorses the observation from the histopathology skin sections. Injection at the
footpad is a common method of studying the clearance by the lymphatic system. The
above data (Fig. 3.4A-C) suggests that InAc-NPs are safe to administer as a vaccine
delivery system [143]

3.3.3. Effect of InAc-NPs on the activation of swine PBMCs
The efficiency and the safety of InAc-NPs as a bioactive vaccine delivery system are well
established through this study (Chapter-II; Fig. 3.4) and previous studies[86]. In adjuvant
research, the success of an adjuvant in one animal species cannot be extended to another
species until proven because of the variation of the PRRs in both structure and
functionality between species [144]. For example, a chemotherapeutic drug Taxol
activate murine TLR4, however, failed as an agonist for human TLR4[145]. Similarly,
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human TLR4 responds to lipid-A but doesn’t get activated by lipid-IVa, whereas both
lipids function as agonists for mouse TLR4 [146]. Therefore, before, advancing with
expensive animal studies using swine model, we tested the ability of InAc-NPs, for the
first time, to activate swine PBMCs. PBMCs have been used as a surrogate model for an
immune function or inflammation studies as they contain lymphocytes, monocytes, and
dendritic cells. Due to their vital involvement in almost any immune development, it very
important to examine their responses to any proposed adjuvant system.
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Figure 3.4. A). In-vitro cellular toxicity of InAc-NPs. Murine dendritic cells (DC2.4)
were treated with InAc-NPs (0-500 μg/ml) for 48 h. The relative cell viability was
determined by using MTT assay with respect to untreated cells (n = 3-4). * indicates
that the results are significant at p ≤ 0.05 vs. untreated cells using one-way ANOVA
followed by Bonferroni's multiple comparison tests. B). Skin toxicity of InAc-NPs.
Histology images of mouse skin sections stained with H&E at the site of injection shows
that InAc-NPs did not form a depot or caused any gross structural damage at the
injection site. C) In-vivo clearance of InAc-NPs from the injection site. Mice were
injected with 1 mg of InAc-NPs loaded with near-IR dye on the right foot pad. The
clearance of vaccine from the injection site was studied by imaging the mice at different
time points after injection till 30 hrs.
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As a novel TLR4 agonist, InAc-NPs were able to activate swine PBMCs to
release critical cytokines (IL-6, IL-12, and TNF-α) necessary for immune activation as
shown by quantified RNA transcripts using real-time-PCR. Nanoparticles prepared with
an inert polymer PLGA were used as a control. InAc-NPs enhanced the expression of IL6, IL-12, and TNF-α by approximately 10, 140 and 12 folds, respectively as compared to
medium or PLGA-NPs (Fig. 3.5). Cytokine such as IFN-γ, TNF-α, IL-12, and IL-6 are
important signals for immune activation. For example, The IFN-γ is one of the main
cytokines that represents cell-mediated immunity, which is also an important factor that
controls the antibody isotype switching to IgG2a [147, 148]. The significant release of
these cytokines indicates the ability of InAc-NPs to activate swine originated immune
cells [149].
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Figure. 3.5. Activation of swine peripheral blood mononuclear cells (PBMCs) Swine
PBMCs were incubated with following formulations (i) Medium (ii) PLGA particles (200
µg/ml) or (iii) InAc particles (200 µg/ml) for 24 hrs. The activation of PBMCs after
treatment was measured by determining the level of transcription genes of IL12 (A), IL6
(B) and TNF-α (C), using real-time PCR. Fold change in mRNA levels was calculated with
respect to the levels of non-stimulated (medium treated) cells. *indicates that results are
statistically significant as compared to medium treated cells. Data are expressed as mean ±
standard deviation of triplicate determinations.
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3.3.4. Swine immunization with M2e antigen delivered through InAc-NPs
Once it is confirmed that InAc-NPs can activate swine immune cells ex-vivo (Fig. 3.5),
in-vivo immunization studies were conducted to assess the potential adjuvant activity of
InAc-NPs using M2e as an antigen. The M2e sequence was a consensus sequence from
multiple swine influenza type-A viruses[150]. The M2e peptide (20 µg) was delivered
either in sterile saline or loaded in InAc-NPs through the subcutaneous and intranasal
route as primary and booster doses. Two weeks after each immunization, serum antibody
titers (total IgG) specific for M2e were measured using ELISA. InAc-NPs as a delivery
system produced 20-fold higher total IgG titers in the serum compared to saline after
subcutaneous booster immunization (Fig. 3.6). Similarly, intranasal administration of
M2e-encapsulated in InAc-NPs (M2e-InAc NPs) has augmented the titers of M2especific IgG antibody 4-fold more than intranasal M2e in saline (Fig. 3.7). Production of
very high titers through intranasal vaccination is significant for a weak antigen like M2e
because of poor retention of the formulations in the nasal cavity of pigs due to the
anatomical structure of the nasal area in the pig and frequent exhale reflection
mechanisms. However, the strong results indicate that the thermo-gel supportive
formulations may have contributed to an improved activity along with the adjuvant
effects of the InAc-NPs as a TLR4 agonist. Although M2e protein is considered as a
weak immunogen, several studies have shown that it is effective in inducing crossprotection after intranasal and systemic immunization in mice with appropriate
adjuvant(s) or delivery systems[151].
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Figure 3.6. M2e specific serum IgG-total antibody titers in subcutaneously
immunized pigs. Pigs (n = 5) were injected subcutaneously with M2e encapsulated
InAc-NPs or with unadjuvanted M2e in saline (25 µg) on days 1 and 21.
Commercial adjuvant Addvax® was used as a positive control. Sera were collected
at 2 weeks after the primary and booster immunizations for the analysis of IgG titers
against M2e peptide using indirect-ELISA. Data was analyzed by one-way
ANOVA followed by Mann-Whitney test. Data was considered significant at pvalue <0.05 in comparison to M2e in saline. The Y-axis was plotted on log10-scale.
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Figure 3.7. M2e specific serum IgG-total antibody titers in intranasally immunized
pigs. Pigs (n = 5 per group) were injected intranasally with M2e encapsulated InAc-NPs or
with unadjuvanted M2e (25 µg) on days 1 and 21 using 1 ml syringe connected to atomizers.
Sera were collected at 2 weeks after the primary and booster immunizations for analysis of
IgG titers against M2e peptide using indirect ELISA. Data was analyzed by one-way
ANOVA followed by Mann-Whitney test. Data was considered significant at p-value <0.05
in comparison to M2e in saline.
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Figure 3.8. M2e specific sIgA antibody titers in immunized pigs. Pigs (n = 5 per group)
were intranasally or subcutaneously immunized with M2e (25 µg) through InAc-NPs or in
saline on days 1 and 21. BALFs were collected 3 weeks after booster immunization. sIgA
titers against M2e in the BLAF fluid were quantified using indirect-ELISA. Data represents
mean ± standard deviation (n=4-5). Data was analyzed with one-way ANOVA followed by
Mann-Whitney test. ** represents that the data was significant at p<0.05 vs M2e in saline.
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3.3.5. M2e-InAc NPs induce of H1N1-specific sIgA antibody response in the lungs

Beside the increase of M2e-specific serum IgG titers in pigs immunized with InAc-NPs,
local antibodies at the major site of infection that recognized M2e were also detected in
BAL fluid collected from pigs after challenge with H1N1 influenza virus. We observed
higher M2e-specific IgA titers in BALF from the pigs vaccinated with InAc-NPs as an
adjuvant compared with the pigs immunized without an adjuvant. The increased response
was observed for both intranasal and subcutaneous groups (Fig. 3.7 A and B). Mucosal
M2e-specific IgA antibodies found in the lungs are vital for clinical protection of the local
airways from influenza virus infection [114]. Mucosal M2e-specific IgA antibodies in the
BAL fluids were detected as early as five days after virus exposure, which suggest a
significant role that local sIgA plays in defending against M2e induced disease. The
induction of high levels of serum IgG and lung IgA against a conserved antigen such as
M2e as shown in this study along with HA as antigen will provide a greater opportunity for
protection from homologous and heterologous influenza virus infection [152].
Viral diseases are a serious threat not only to the productivity of today's swine farms
but also to food safety, and human/farmer health[153]. The major limitations in today’s
animal vaccines against viral diseases are antigenic drift, lack of potency to stimulate cellular
immune responses, lesions at the injection site, instability and the high cost of the
formulation. These challenges could be addressed with an appropriate vaccine adjuvant as
identified in this study (InAc-NPs).
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3.4. Conclusions
In conclusion, these results show that prime and boost vaccination with M2e-InAc NPs
elicits antigen-specific mucosal and systemic immune responses to an influenza virus
antigen in a large animal model such as swine. The current study for the first time
showed that a polymer-based TLR4 agonist InAc could activate the pig immune system
to generate strong humoral and mucosal immunity. This study has created a pathway for
more extensive studies in our laboratory, that are currently undergoing to generate strong
systemic and mucosal antibodies against HA and M2e peptides. The findings of this work
will not only pave the way to significantly improved pig influenza vaccines but also
provide a new platform technology for other viral vaccine formulations for both human
application and swine industry.
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Chapter-IV
A Multifunctional Vaccine Delivery System with Dual
Adjuvants: TLR4 and TLR7 Agonists
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4.1. Introduction
Recently, protein subunit and nucleotide-based vaccines have become more popular than
live attenuated or killed vaccines, due to their enhanced safety profile, ease of
manipulation and production through recombinant DNA technology, and their utility
against cancers using cancer specific antigens[154]. However, subunit vaccines have low
immunogenicity and require co-administration of an immune-stimulant/adjuvant [77].
The modern vaccine adjuvant development is focused on activating the innate immune
system through the discovery of ligands for pattern recognition receptors (PRRs). Tolllike receptors (TLRs) represent one of the most popular groups of PRRs and their
agonists have been explored as vaccine adjuvants [155]. TLRs are highly expressed on
antigen-presenting cells, such as macrophages and dendritic cells, which play a critical
role in communicating to the adaptive immune system to direct the type and magnitude of
the vaccine or pathogen response. TLR-agonists have been developed as vaccine
adjuvants against both infectious diseases and cancer, with several of them currently in
clinical use [26, 156, 157].
Thirteen TLRs have been discovered in mammals so far, with 10 TLRs (TLR110) identified in the human genome [16]. Of all the TLR agonists, TLR4, TLR3, TLR7/8,
and TLR9 ligands have been extensively explored in vaccine research mainly due to their
ability to stimulate cell-mediated immunity[26]. TLR4 agonists such as monophosphoryl
lipid-A (MPLA) have been explored as immune stimulants in various vaccines. One of
the licensed and marketed vaccines Cervarix, a prophylactic vaccine for cervical cancer
consists of MPLA and alum in the form of AS04 as a vaccine adjuvant[48]. Recently,
several TLR7 agonists including Resiquimod (R848) and Imiquimod (R837) have been
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explored for cancer immunotherapy due to their ability to activate cell-mediated
immunity[43, 158]. Substantial interest has been shown in using the synergistic effect of
the combination of TLR agonists to enhance immunogenicity and the efficacy of vaccines
esp. against cancers[159] [26]. For instance, co-administration of MPLA and CpG-rich
oligonucleotide (CpG, a TLR9 agonist) has been shown to activate APCs via two
different pathways, with a synergistic effect that boosts cellular and humoral immune
response [92, 160]. The combination of TLRs 7, 8 and TLR9 agonists has been shown to
augment CTL and NK tumor cell infiltration, eradicate large tumor masses and launch
long-term protective immunity [161]. In choosing an appropriate delivery system for a
combination of TLR agonists, it is critical to consider the localization of TLRS within
APCs. A set of TLRs is located on the surface of APCs (E.g. TLRs-2,4,5, etc.), while
another set is at the membrane of endosomes/phagosomes (TLRs-7,8, 9, etc.). Therefore,
for endosomal TLRs, there is need to deliver the ligands to the target site, which is inside
endosomes or phagosomes.
A combination of TLR agonists can be efficiently delivered to APCs by using a
polymeric particulate delivery system, along with the antigen(s) [26]. The advantages of
using polymeric particles for co-delivering a combination of adjuvants include lower
clearance from the injection site, sustained stimulation for efficient APC activation, and
priming the same APC with both the adjuvantss to activate multiple signaling pathways
[55]. In addition, particulate delivery systems can deliver multiple antigens along with
adjuvants, to phagocytic cells such as APCs more efficiently than a physical combination.
This is due to the inherent function of APCs as phagocytic cells to recognize and engulf
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particles. Particulate systems can also be modulated to required size and shape to enhance
the immune recognition [162, 163].
Previously, our laboratory reported on the discovery of a novel TLR4 ligand,
inulin acetate (InAc), which is a modified polysaccharide [84, 86]. A pathogen-like
particulate vaccine delivery system (PMVDS) was designed, taking advantage of immune
activating and the hydrophobic polymeric nature of InAc [85]. PMVDS is a functional
vaccine delivery system with the inherent property of activating TLRs on APCs.
Furthermore, it is highly efficient in delivering the antigen to the phagosomes/endosomes
of APCs due to its particulate nature and its interaction with surface TLR4 [164, 165]. In
comparison to PLGA particles with similar physicochemical properties, InAc particles
delivered 6.2 times more antigen to dendritic cells [85]. Simultaneously, Dr. Ferguson
group has recently reported several small molecular-based synthetic TLR7/8 ligands,
including the compound C-563, a TLR7-specific ligand. TLR7 is present in the
endosomes; therefore, its agonists need to be delivered to the endosomes for receptor
activation. We hypothesized that by delivering C-563 through InAc nanoparticles (InAcNPs), C-523 can be delivered to endosomes very efficiently and importantly, activate
multiple pathways for strong immune activation.
In this study, aTLR7 agonist C-563 was encapsulated into InAc-NPs (a TLR4
agonist) (InAc-563 NPs). The efficiency of antigen delivery and immune stimulant
properties of InAc-563 NPs were investigated using murine macrophages from wild-type
and TLR4 and TLR7 knock out mice. Immunization studies in mice confirm the
synergistic effects of the dual targeting by InAc-563 NPs, as indicated by strong
antibodies titers in the serum and cytokine response in the ex-vivo splenocyte culture that

88

represents signals for both humoral and cell-mediated immunity. InAc-563 NPs provided
a plat form technology both as a potent vaccine adjuvant and as a delivery system for
antigen and/or other endosomal TLR ligands.

4.2. Materials and Methods
4.2.1 Materials
Soluble inulin with an average molecular weight of 5 KDa was purchased from MP
Biomedicals LLC, Santa Ana, CA, USA. Poly (lactic-co-glycolic acid) PLGA was
purchased from Sigma-Aldrich, St Louis, MO, USA. A small molecule imidazoquinoline
analog (C563) was obtained from Ferguson Lab, University of Minnesota, Minneapolis.
Imiquimod (R837) and Monophosphoryl lipid A (MPLA) were purchased from
Invivogen, San Diego, CA, USA. All other chemicals were purchased from Fisher
Scientific, Pittsburgh, PA, USA.
4.2.2

Cell lines and mice

Macrophage cells from Wild-type (NR-9460), TLR7 knockout (NR-915634) and TLR4
knockout (NR-9458) mice were obtained through BEI Resources, ATCC, Manassas, VA,
USA. The macrophages were plated in complete RPMI-1640 medium (Thermofisher
Scientific, USA), supplemented with antibiotics (penicillin/streptomycin) and 10% fetal
bovine serum (FBS) in flat-bottom 24-well plates at a concentration of 0.5 x 105
cells/ml/well unless specified elsewhere. They were cultured in a 5% CO2 incubator at
37°C. BALB/c mice were purchased from Jackson’s Labs (Maine, USA) and experiments
were performed at 6 –12 weeks of age. All experiments were performed following The
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Animal Care and Use Committee Experimentation Standards at the South Dakota State
University, Brookings, SD, USA.
4.2.3

Preparation of Inulin Acetate-563 nanoparticles (InAc-563 NPs)

Inulin acetate nanoparticles carrying C563 (InAc-563 NPs) and both C563 and
ovalbumin (InAc-563-Ova) were prepared using double (w/o/w) emulsion solvent
evaporation techniques as described elsewhere (Chapter-II). Briefly, an aqueous phase of
the primary emulsion was prepared with a 10 mM phosphate buffer (PB, pH7.4)
containing 2% (w/v) Pluronic F-68 solution as a surfactant, with or without Ova. The oil
phase was prepared by dissolving InAc (100 mg) and C-563 (5 mg) in 5 ml of
dichloromethane (DCM). The aqueous solution was added drop by drop to the DCMpolymeric mixture to form a primary (w/o) emulsion, which was subsequently added
drop-wise into 45 ml of water containing 0.5% (w/v) polyvinyl alcohol while stirring at
200 RPM. To evaporate DCM, the final emulsion was stirred for 12 hrs., and the
precipitated particles were collected via centrifugation at 50,000 g for 30 min at 4°C. The
particles were washed twice, re-suspended in 100 mM of citrate buffer, pH of 7.4 and
lyophilized with mannitol (20% w/w) (VirTis, Gardiner, NY).
4.2.4

Size and zeta potential

As described previously, the size and zeta potential were measured by the dynamic light
scattering (DLS) technique using Malvern Zeta-Sizer, Malvern Ltd, MA, USA. InAc-563
was re-suspended in a filter-sterilized citrate buffer (10 mM, pH 7.4) and diluted using
filtered sterilized water before recording particle size and z-potential.
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4.2.2

Scanning electron microscopy (SEM)

The shape and size of InAc-563 NPs were evaluated using a scanning electron
microscope (SEM) (Model S-3400N, Hitachi, Japan) (Engineering Department, SDSU).
For the preparation of the sample, the lyophilized powder, free of cryo-protectant, was
mounted on the metal holder using conductive double-sided tape. The particles were
sputter coated with a 10-nm gold layer before analysis. The micrographs were captured at
a beam voltage of 5 kV, and 50,000X magnification with a working distance of 5-15 mm
and a spot size of three. ImageJ software was used to measure the average diameter of the
particles representing at least 100 particles. Refer to Chapter-II for additional details.

4.2.3

Determination of the loading of C-563 and the antigen in InAc-563 Ova

The amount of C-563 compound loaded into the InAc nanoparticles was measured using
high-performance liquid chromatography (HPLC) (Water Coulter). DMSO was added to
1 mg of nanoparticles to extract the C-563 from the InAc-563 particles, then quantified
using HPLC. The separation was achieved using a 40:60 mixture of ammonium acetate
buffer (pH 4-5) and acetonitrile as the mobile phase, with a flow rate of 1 ml/min through
an Eclipse C-18 reverse-phase HPLC column (Agilent, 4.6 150 mm, particle size 4 mm).
The C-563 was detected and quantified using a UV detector at 254 nm. For measurement
of antigen (Ova) loading, 1 mg of InAc-563 NP was dissolved in 500 µl of acetone. As
InAc-563 NP dissolve in the acetone, Ova was precipitated and then collected in 1%
sodium dodecyl sulfate (SDS). The collected Ova was quantified by a Pierce™
Bicinchoninic acid assay (BCA), refer to Chapter-II for further details.
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4.2.4

In-vitro drug release studies for C-563

In-vitro release of C-563 from InAc-563 NPs was determined using a dialysis technique.
InAc-563 nanoparticles (~ 10 mg/ml) were suspended in PBS (pH 7.4) and incubated in a
shaker (New Brunswick Scientific) at 37°C, 100 RPM. At predetermined time points, a
500 µl of the suspension was collected and centrifuged at 10,000 xg to collect the soluble
supernatant portion. Collected samples were filtered through 0.2 µM filter and then
lyophilized. The C-563 was dissolved in 200 µl DMSO and quantified by using the
HPLC, as described above.
4.2.5

In-vitro immune-activation

Murine macrophages (from wild-type, TLR4, and TLR7 specific knockout mice) were
seeded in 12-well plates (0.5 x 106 cells/well) for 48 hrs in complete RPMI medium,
Macrophages were incubated with InAc-563 NP (250 μg/ml/well) for 24 h. Imiquimod
(5μg/ml/well) and MPLA (2 μg/ml/well) were used as positive controls and media alone
was used as a negative control. The culture supernatants were collected after centrifuging
the plates at 4000 xg. The 100-μl aliquots were analyzed in triplicate for the levels of
TNF-α using TNF-α ELISA Ready-SET-Go Kit (e-Bioscience, San Diego, CA) as
instructed by the kit. TNF-α concentrations were calculated based on a standard curve
that was generated by using purified mouse recombinant TNF-α. The TNF-α level in the
untreated wells was considered a background[85, 166].
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4.2.6

In-vivo immunization in mice

Male BALB/c mice (n = 4–5 per group, 6–8 weeks old) were immunized through a
subcutaneous route (s.c) by injecting 100 μl of vaccine formulations (50 μl per site) using
a 25G needle with the following groups;
i)

PBS (50 mM Phosphate buffered saline, pH 7.2)

ii)

Ova (20 μg per mouse)

iii)

Ova (20 μg) encapsulated inside InAc-563

iv)

Ova (20 μg) physically mixed with InAc-563 NPs.

All the formulations were injected in a sterile vehicle containing 20 % Pluronic F127 gel in PBS. Mice were administered with booster dose three weeks after the initial
immunization. A blood samples were collected three weeks after the primary and booster
immunization and sera were isolated using Microtainer serum separator (BD Biosciences,
San Jose, CA). The sera were stored at -20°C until further analysis.
4.2.10 Enzyme-linked Immunosorbent Assay (ELISA)
The 96-well plates were coated with 1 μg/ml of Ova in a carbonate buffer (pH
9.6) for overnight. The wells were blocked with a PBS containing 1% skim milk after
washing the uncoated antigen. The sera from immunized mice were incubated on the
antigen-coated wells overnight at various dilutions. After washing three times with PBS,
goat anti-mouse total IgG or IgG2a conjugated with horseradish peroxidase (Southern
Biotech) were added at 1:7000 dilution and incubated for 1 hr at room temperature. After
five more washings with the PBS, the plates were incubated with a TMB (3,3′,5,5′-
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Tetramethylbenzidine) substrate for 5-7 min. The reaction was stopped with 50 µl of 1 N
H2SO4, and then the absorbance was measured at 450 nm. Antibody titers were calculated
as dilutions of the serum at which the OD value is equivalent two standard deviations
above the average OD value of the serum from PBS immunized mice (Cut-off OD). AntiOva titers were represented as the highest dilution giving the OD value over the cut-off
OD value.
4.2.11 Splenocyte Activation assay: ex-vivo
T-cell proliferation assay was used to determine the generation of memory T-cells in
immunized mice after being challenged with the antigen in ex-vivo conditions as
described previously[85]. Briefly, single cell suspensions of the splenocytes were
prepared from the spleens of immunized mice in RPMI-1640 medium supplemented with
10% heat-inactivated fetal bovine serum (FBS), 1% penicillin/streptomycin, 1 mM
sodium pyruvate and 50 μM 2-mercaptoethanol. The erythrocytes were eliminated using
0.1 M NH4Cl lyses buffer, and the viability of resultant splenocytes was assessed by
trypan blue exclusion using a Cellometer (Nexcelom Bioscience, Lawrence, MA). The
splenocytes (1 × 106 cells/well) seeded in triplicate into a 96-well plate were challenged
with Ova (100 μg/ml) or with concanavalin A (5 μg/ml; Con A; Sigma) as a mitogen.
Splenocytes incubated with medium alone were used as a negative control. After three
days of incubation at 37° C (5% CO2, 95% humidity), the plates were centrifuged for 10
min at 1000 xg to pellet the cells, and 200 μl of supernatant was collected for the analysis
of secreted cytokines.
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4.2.12 Cytokine analysis
Sandwich-ELISA assay was used to measure the cytokines in the supernatants of the
splenocytes culture. The assay was performed using a Mouse Th1/Th2 ELISA ReadySET-Go Kit (e-Bioscience, San Diego, CA). Th1-type (interleukin-2 [IL-2], gamma
interferon [IFN-γ] and Th2-type (IL-4 and IL-10) cytokines were measured by comparing
them with the standard curves generated from murine recombinant cytokines (IL-2, IL-4,
IL-10, and IFN-γ) after linear regression analysis [99].
4.2.13 Determination of endotoxin levels
The endotoxin levels in the final preparation were determined using the ToxinSensor™
Chromogenic LAL Endotoxin Assay Kit from GenScript (Piscataway, NJ), following the
manufacturer's instructions. All formulations used in this study have a low detection limit
of endotoxins as per the United States Pharmacopeia for parenteral administration [96].

4.2.14 Statistical analysis
Results were expressed as mean ± standard error (SD) unless specified. All presented
data were analyzed with Instant Graph Pad software (CA) and tested by Student's t-test
one-way or two-way ANOVA, for the analysis of variance, as required. Additionally,
Bonferroni's or Dunnett's post-hoc multiple comparison tests for statistical significance
were performed and P<0.05 was considered a statistically significant difference unless
otherwise mentioned in the figure legends.
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4.3 Results and Discussion
The limited availability of safe vaccine adjuvants in the market warrants the discovery of
new vaccine adjuvants targeted towards specific innate immune signaling pathway such
as TLR or NLR pathways. Several TLR agonists, esp. against TLR4, TLR7 and TLR 9,
have been investigated for the design of modern vaccines against viral diseases and
cancer[16] [167-169]. Previously, we demonstrated that an immune active nano-vaccine
delivery system prepared with a TLR4 agonist (InAc) as a polymer (InAc-NPs)
significantly increased the serum antibody titers and cell-mediated immune response
against an injected antigen [85]. In previous studies, co-injection of antigen with InAc
particles failed to significantly activate the immune system as an adjuvant [Chapter-II]. It
was necessary to encapsulate the antigen inside InAc-particles to produce a robust
humoral and cellular immune response. In this chapter, we examined the efficiency of a
novel combination of TLR4 (InAc) and TLR7 agonists (C-563) as an adjuvant and a
vaccine delivery system using both in-vitro and in-vivo models. A small molecular TLR7
agonist, C-563, was encapsulated in InAc-NPs to deliver them together (InAc-563 NPs).

4.3.1 Physicochemical characterization of InAc-563 NPs
The InAc-563 NPs were characterized by their size, shape, charge, antigen loading,
loading of C-563, and endotoxin level. HPLC analysis showed that 3.5 µg ± 0.24 of C563 was encapsulated per 1 mg of nanoparticles. The loading of C-563 into InAc-NPs
was around three times higher than the level reported for similar compounds with PLGANPs [170]. The NPs had an average diameter of approximately 289 nm with a slightly
negative charge (-0.62), as determined by dynamic light scattering (DLS) (Fig.4.1.A-C).
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Further, scanning electron microscopy (SEM) images revealed spherical particles with an
average diameter of 280 ± 6.2 nm (Fig. 4.1 B) [Table 4.1]. Nanoscale structures of InAc563 particles were meant to increase the contact with APCs at the site of injection,
facilitate the uptake of the antigens and improve the delivery to the lymphoid tissue for
proper bio-distribution [100]. The literature review in Chapter-I clearly established the
advantages of nanoparticles for vaccine delivery, as APCs preferentially phagocytose
them and elicit stronger cytokine release compared to microparticles [156] [102]. In this
regard, the nanoparticle delivery system has also been shown to augment mucosal
immunity after intranasal vaccination [Chapters I & II]. Polymeric nanoparticles
encapsulating different TLR agonists have been investigated for improved immune
activation. PLGA nanoparticles are the most commonly used carriers for TLR agonists.
For example, PLGA particles encapsulating a TLR9 agonist (CpG) resulted in greater DC
uptake, maturation and T-cell activation [103]. However, the versatility of inulin acetate
nanoparticles as carriers emerges from their inherent ability to activate the innate immune
system through TLR4 [86] and superior ability as an antigen delivery system[85].
Since inulin acetate targets TLR4 on the cell membrane of the immune cells,
InAc-NPs significantly facilitate cargo uptake into the phagosomes/endosomes of APCs,
thereby expected to delivery C-563 to the site of TLR7 localization. In addition to
carrying the TLR7 agonists, InAc-NPs were also loaded with the antigen. Antigen
loading was determined by precipitating the antigen in acetone, extracting it using a
surfactant (SDS) and quantifying it by BCA assay. Approximately 21.0 ± 0.47 µg of
ovalbumin was loaded for every milligram of InAc-563 NPs, which is consistent with
previous reports[86] [85]. The NPs are expected to deliver the antigen efficiently to the
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APCs of the innate immune system, a major target site for vaccines [171]. The particle
uptake by APCs was influenced by particle size, antigen loading and exposure time
[110]. Despite being hydrophobic, InAc-563-NPs efficiently encapsulated both the
protein antigen (Ova) and the small molecular TLR agonist, C-563 (Table 3.1).
Previously, we demonstrated that the antigen encapsulated inside InAc particles was
released in a sustained pattern over days (Chapter-II, Fig.2.3) [84].
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Figure 4.1. Characterization of InAc563 nanoparticles. (A) Particle size
distribution measured using DLS as
percent intensity. (B) Scanning electron
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nanoparticles with spherical morphology.
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Similar to the release of antigen, the encapsulated C-563 was also released from the
InAc-NPs in a steady and sustained manner. Although 20-30% of the antigen was
released within the first 30 minutes (burst release), possibly due to a surface-adsorbed
antigen, such a dual release pattern was not observed with C-563 (Fig. 4.2). Zero percent
of the C-536 was released within the first 30 min, while approximately 1.33% of total
encapsulated C-563 was released in the first 2 hrs. of incubation (Fig. 3.2).

Table.4.1: Physiochemical characterization of InAc-563-Ova.

Particle Size (diameter)

289 ± 0.61 nm

Zeta-potential

-0.71

Polydispersity index

0.31

Loading of C-563 (µg/mg NP)

3.5

Loading of antigen (Ova)(µg/mg NP)

21 ± 0.48

Data represent the mean ± standard deviation (n=3). Loading indicates the amount of the
substance (µg) present in one milligram of the nanoparticles (NP)

99

% Cumulative Release of C-563

100
80
60
40
20
0
0

5

10

15

20

Time (Days)

Figure 4.2 In-vitro release kinetics of C-563 from InAc-563 NPs. The NPs (10 mg /ml)
were dispersed on 0.1 M PBS at pH 7.4 with at ~100 RPM. At different time intervals,
soluble samples were collected and lyophilized. The amount of C-563 present in the
lyophilized powder was estimated using RP-HPLC after extracting with DMSO. The data
represent mean ± SD with three repetitions.

4.3.2 InAc-563 NPs activate macrophages via TLR stimulation
For the activation of APCs, murine macrophages were treated with blank InAc-563 NPs
without the antigen. The activation was assessed by measuring the secreted cytokine
TNF-α. InAc-563 NPs activated murine macrophages similar to other TLR agonists such
as MPLA and imiquimod (Fig. 4.3A). This data is consistent with our previous reported
work, where InAc particles activated several other APCs, including dendritic cells and
microglial cells [84, 86] (Chapter-II, Fig. 2.4). However, the same concentration of InAc563 NPs failed to activate macrophages lacking functional TLR4 receptor, indicating that
the presence of TLR4 is necessary for the activity of the InAc delivery system as an
immune-stimulant. MPLA, a known TLR4 agonist showed similar pattern as InAcparticles (Fig. 2.4). Despite the presence of TLR7 agonist (C-563), InAc-563 NPs failed
to stimulate macrophages from TLR4-/-, which suggests that C-563 may not be delivered
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to phagosomes, the target site, in significant amounts by InAc-NPs in the absence of
TLR4. This is a confirmation of our previous reports that InAc activates APCs through
TLR4 receptors using LPS-RS, a pharmacological antagonist of TLR4 (Chapter-II, Fig.
2.4).
Interestingly, InAc-563 NPs have partially stimulated macrophages from the
TLR7 knockout mice (TLR7-/-) whereas imiquimod (TLR7 agonist) completely failed to
activate TLR7 knockout cells. The data indicate that the polymer InAc used in the
preparation of InAC-563 NPs may have contributed to the activation of TLR7-/- cells
through surface TLR4. However, the role of other TLRs cannot be ruled out (Fig.4.3B).
Taken together, the above data suggest that InAc-563-NPs have a dual activity that
activates both TLR4 and TLR7 receptors, which could complement in-vivo immune
stimulation as a multifunctional vaccine delivery system. The combination of synthetic
small molecular ligands of TLR4 (MPLA) and TLR7 has been shown to generate longlived cellular and humoral immunity[172]. The above combination has been shown to
work through Myd88-dependent signaling pathway[172]. The previous report from our
laboratory established that InAc-particles also function through Myd88-dependent
pathway[84]. Combining two TLR ligands within a formulation not only allow dosesparing of antigen and adjuvant but also enables broad protection.
Macrophages and other APCs show high expression of TLRs, either on their
surfaces or in the endosomes in the cytoplasm (Chapter-I); thus, their activation has a
strong and dynamic influence on regulating pathogen invasions and their clearance[55].
In a separate study, C-563 and other related compounds demonstrated specific targeting
of TLR7/8 on bone marrow-derived dendritic cells[173]. Our previous studies have

101

revealed the immunostimulant properties of InAc particles on dendritic cell, microglia
and macrophage cells (Chapter-II). In addition, InAc particles have been shown to
activate peripheral blood mononuclear cell (PBMCs) from the human and porcine origin
(Chapter-III). Multiple studies confirmed the efficiency of InAc-NPs in delivering
antigens to APCs [84-86] (Chapter-II, Fig.2.5). The presence of C-563 did not interfere
with the antigen delivery function of InAc-NPs (Fig. 4.4). InAc-563 NPs may activate
APCs through multiple mechanisms: better antigen delivery, persistent antigen delivery
inside APCs (antigen persistence), activation of both TLR4 and TLR7, and efficient
delivery of C-563 to the target site (endosomes) (Fig. 3.4). Taken together, the in-vitro
data suggests that InAc-563-NPs represent both a potent delivery system for antigens and
other adjuvants, as well as an immune potentiator.
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Figure 4.3. Macrophage activation of InAc-563 NPs. Macrophage cells (𝜽)
originated from wild-type (WT), TLR4 knockout (TLR4-/-) (A), TLR7 knockout
(TLR7-/-) (B) mice were incubated with MPLA (2 μg/ml), a known synthetic TLR4
agonist, imiquimod (5 μg/ml), a known synthetic TLR7 agonist, or InAc-563 NPs
(250 μg/ml) without antigen. The activation of macrophages was measured by
estimating the concentration of TNF-α in the culture supernatant after 24 hrs of
incubation. ** indicates results are statistically significant as compared to knockout
cells (P < 0.001). The experiments were performed in triplicate.
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Figure 4.4 Internalization of InAc-563 NPs by macrophages Wild-type
macrophage cells were incubated with FITC-Ova encapsulated InAc-563 NPs at 37
ºC. After 1 hr the cells were extensively washed, fixed in 4% (w/v) paraformaldehyde
and observed under a fluorescent microscope. The nucleus was stained with DAPI.
Scale bars are equal to 10 µm ( )

4.3.4. InAc-563 NPs generates strong serum antibody titers in mice
Once established in vitro that InAc-563 NPs function as both a delivery system and
immune activator (macrophages), their efficiency as a vaccine adjuvant was investigated
in male BALB/c mice with two doses with a 3-week apart [174]. After three weeks of
primary immunization, the Ova loaded inside InAc-563-NPs, and Ova as a physical
mixture with InAc-563 NPs produced significantly strong serum antibody titers (IgG1
and IgG2a), compared to the Ova without adjuvant (p<0.001) (Fig. 4.4A). After a booster
dose, the Ova-loaded InAc-563 NPs stimulated 150-fold higher serum IgG1 titers
compared to Ova alone. The physical mixture of Ova with InAc-563-NPs also produced
strong IgG1 titers in the serum (81- fold vs. Ova alone). Similarly, InAc-563 NPs loaded
with Ova (67-fold), and the physical mixture with InAc-563 NPs (47-fold) produced
strong IgG2a titers in the serum (Fig. 4.5B).

104

Interestingly, previous administration of InAc particles that were physically
mixed with Ova produced significantly lower antibody titers than the current study.
Previously, the physical mixture of InAc microparticles with Ova generated just a 2-fold
(IgG1) greater response than Ova alone [85]. In this study, with the addition of thermogel, InAc-563 NPs were able to generate an 81-fold increase over Ova alone. The
explanation for that high response is related to the use of the thermo-gel as an Ova
vehicle which allowed the presence of TLR agonists and antigens together within
phagosomes of APCs or the addition of C0563 as a dual adjuvant,. This determined the
efficiency of the antigen presentation by MHCs and critically directed the adaptive
immune response [85]. Indeed, by changing the context of antigen presentation, the type
of adaptive immune response was altered [85, 86]. Previously, when InAc particles were
delivered along with the antigen in saline, the antigen might have diffused out from the
injection site faster than the particles, which adversely affect the co-delivery of the
antigen and the adjuvant to the same cell. Such co-delivery was achieved in this study,
either by encapsulating the antigen within the particles of InAc-563 or by delivering them
in the thermo-gel formulation. The thermo-gel formulation is liquid at 4 C for the ease
of injection and assumes a solid matrix form at body temperature to retain the antigen and
the adjuvant (InAc-563) for a longer period at the site of the injection, allowing more
exposure to the peripheral APCs [174].
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Figure 4.5. Ova-specific antibody titers in the serum. Mice (n = 4 per group) were
injected Ova (20 µg) in solution or Ova along with InAc-563 NPs as a physical mixture
(InAc-563 NPs + Ova) or Ova loaded inside InAc-563 NPs on days 1 and 21 as primary
and booster doses, respectively. Serum samples were collected at 3rd week after the
immunizations for analysis of antibody titers (IgG-1, and IgG-2a) using indirect ELISA.
The titer is the reciprocal end serum dilution at which the absorbance is more than average
absorbance plus two standard deviations from the PBS-immunized mice serum. The data
represents mean ± SD, plotted on logarithmic scale.

The previous reports and Chapter-II noted that intradermal and internasal
immunization of InAc-based particles showed robust serum-IgG1 and IgG2a titers, which
are attributed to the function of InAc-NPs as both adjuvant and antigen delivery system.
The results in this study signify, for the first time, the importance of the adjuvant
properties of InAc-563 NPs beyond a delivery system (physical mixture). However, we
cannot rule out the additional immune-stimulatory activation through TLR7 signaling
contributed by the C-567 in the adjuvant properties observed in this study.
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4.3.5 InAc-563 NPs generate both humoral and cellular cytokines in ex-vivo
splenocyte challenge
Many studies have shown the direct relationship between APCs' response to PAMPs
through PRRs, and the activation and expansion of antigen-specific memory T-cells
representing both humoral and cellular responses [175]. Mice immune response was
further assessed indirectly for the generation of antigen-specific memory T-cells by
challenging splenocytes collected from the spleens of immunized mice with the antigen.
Splenocytes were challenged ex-vivo cultures with ovalbumin and the resultant release of
IL-2, IFN-γ, IL-4 and IL-10 into the supernatant were quantified (Fig.4.6 and Fig.4.7 ).
The splenocytes collected from the mice immunized with Ova encapsulated in
InAc-563 NPs or as a physical mixture generated significantly higher levels of both Th1and Th2-type cytokines, as compared to splenocytes from the mice immunized with
soluble Ova in a thermo-gel (p<0.001). The antibody subclasses indirectly indicate splits
in the T-helper cell (Th) response, in which IgG1 is linked to the Th2-type response and
IgG2a is linked to the Th1-type response [176]. The results concluded that InAc-563-NPs
as an adjuvant and/or a delivery system generated strong humoral and cellular immune
responses as evidenced by significantly higher IgG1 and IgG2a antibodies (Fig.3.4) and
the induction of cytokines represents both cellular (IL-2 and IFN-γ) and humoral (IL-4
and IL-10) immune responses.
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Figure 4.6. Measurement of Th2-type cytokines (IL-4 and IL-10). Splenocytes
were prepared from mice immunized with soluble Ova (Ova), soluble Oval along
with blank-InAc-563 NPs or Ova-loaded InAc-563 NPs. The splenocytes were
cultured for 72 hrs in presence of Ova (100 µg/ml). After the incubation, supernatant
from different treatment groups were collected and the concentration of different IL4 and IL-10 were measured using sandwich-ELISA. ** indicates results are
statistically significant as compared to ova immunized group (P < 0.001).
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Figure 4.7. Measurement Th1-type cytokines (IFN-γ and IL-2). Splenocytes were
prepared from mice immunized with Ova form or Ova with InAc-563 NPs ova loaded in
InAc-563 and cultured for 72 hrs in presence of Ova (100 µg/ml). Supernatant from
different treatment groups were collected and the concentration of different IFN- γ and IL2 were measured using Sandwich-ELISA. ** indicates results are statistically significant
as compared to Ova alone immunized group (P < 0.001).

TLR4 is one of the extensively studied TLRs as a target for vaccine adjuvant
discovery. Indeed, a synthetic TLR4 agonist, MPLA in combination with alum (ASO4) is
a part of two commercial vaccines Fendrix, a vaccine for hepatitis B, and Cervarix, a
vaccine for human papillomavirus [177-180]. MPLA is produced after extensive
chemical modification of biologically originated lipopolysaccharides (LPS), which
results in large variability from a batch to batch and high cost of the final product. To
overcome the above challenge, a polysaccharide polymer based inulin acetate (InAc) was
discovered as a TLR4 agonist [84]. A major advantage of InAc is that it can be used as
material to prepare a vaccine delivery system (InAc NPs) that can inherently activate
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TLR4 on APCs [85]. InAc NPs are based on a modified polysaccharide from plant origin.
The procedure is simple to prepare and economical for commercialization.
Of all endosomal TLRs, TLR7/8 are broadly expressed on most of the APCs
including plasmacytoid dendritic cells (pDCs) in contrast to TLR9, which is primarily
expressed on pDCs. The expression pattern translates into better adjuvanticity for synthetic
TLR7/8 agonists compared to TLR9 agonists such as CpG ODNs [181]. However,
unformulated small molecular TLR7/8 ligands do not work well as vaccine adjuvants
mainly because of their quick diffusion from the injection site, which may cause systemic
toxicity, and their inability to reach the target site (endosomes/phagosomes)[182].
Combinations of TLR4 and TLR7 ligands were examined as adjuvants in different
models and stages, reporting promising results in preclinical trials esp. against viral
diseases and cancer [172, 182]. A TLR4 agonist such as MPLA and TLR7 agonists such
as imiquimod are hydrophobic in nature and require a formulation to deliver (Eg. polymeric
particles, emulsion, liposomes, etc.). In addition, a particulate formulation (Eg.
Nanoparticles, liposomes or micelles) will reduce the diffusion of the inflammatory TLR7
agonists and promote their uptake by APCs such as macrophages [182]. In this study, by
encapsulating C-563 inside InAc NPs along with the antigen, we could achieve both the
delivery requirement for TLR7 agonist and dual adjuvanticity of activating TLR4 and
TLR7.
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4.4 Conclusion
The in-vivo and in-vitro studies suggest that the InAc-563 NPs-based vaccine delivery
system, with TLR4/7 ligands, could facilitate strong immune response with or without
encapsulation of the subunit antigen. In mice, the delivery of InAc-563 NPs led to a
stronger antigen-specific serum antibody response. InAc-563 NPs function as both
vaccine adjuvant and a vehicle to deliver C-563 and antigen. This work provides a unique
platform technology using InAc-563 nanoparticle as multifunctional vaccine delivery
system against challenging diseases such as viral diseases and cancer, where cellmediated immune activation is necessary.

111

Summary and Future Studies
Because of recently evolving respiratory pathogens (viral and bacterial), growing
antibiotic resistance coupled with rising occurrences of inflammatory mucosal diseases,
there is an urgent medical need for discovery of a novel vaccine technology that activates
both systemic and mucosal protection. However, there is a serious paucity in the
availability of vaccine technologies or vaccine adjuvants to address the above need. The
above limitation has hampered the development of successful preventive vaccines against
challenging mucosal pathogens such as HIV, HPV, influenzas, tuberculosis, etc.
Towards addressing the above goal, previously, our laboratory reported a
“pathogen mimicking vaccine delivery system” (PMVDS) prepared with inulin acetate, a
TLR4 agonist as a polymer. PMVDS was successfully tested previously through
subcutaneous or intradermal route to generate strong systemic immunity for a skin cancer
vaccine (Melanoma) using peptide antigens. However, through parenteral routes of
administration failed to produce detectable mucosal immunity.
The main goal of this dissertation is to investigate the potential of InAc based
nanoparticles (InAc-NPs) as a mucosal adjuvant and delivery system alone or in
combination with other adjuvants. Based on the previous promising results and existing
literature, we hypothesize that of nano-PMVDS (InAc-NPs) have potential to generates
strong systemic and mucosal immune responses if given intranasally. As in Chapter-II,
intranasal delivery of InAc-NPs induced high levels of secretorty IgA (sIgA) in the nasalassociated lymphoid tissue (NALT) and IgG1 and IgG2a in the serum with a wellbalanced Th1- and Th2-type responses. In addition to antibody secretion at nasal tissue,
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other distinct mucosal tissues (lungs and intestine) had also shown high levels of sIgA.
The high efficiency of InAc-NPs as a delivery system and adjuvant was supported by
various in-vitro mechanistic investigations that showed improved antigen delivery and
strong activation of macrophages in TLR4 dependent manner by InAc-NPs.
Once the proof-of-the-concept that InAc-NPs could provide efficient platform
delivery system for mucosal vaccines is established using artificial antigen (Ova) in mice,
we advanced the concept to test in larger animals like pigs with disease-relevant antigen
(influenza-M2e) in chapter-II. InAc-NPs activated pig primary immune cells (PBMCs) to
release inflammatory cytokines necessary for vaccine efficiency. Importantly, when
immunized through InAc-NPs as a delivery system, a weak antigen like M2e peptide
produced higher systemic (20-fold) and mucosal (1.45 fold) antibody response in pigs.
This is a preliminary study that signifies the ability of InAc-NPs as an adjuvant and a
delivery system in pigs. More studies are underway in our laboratory to advance towards
generating a universal influenza vaccine using HA and M2e as antigen and testing them
for protection against homologous and heterologous strains of influenza.
In addition, being a TLR4 agonist (adjuvant), InAC-NPs are reported as an
efficient targeted vaccine delivery system to deliver the encapsulated antigen (cargo) to
the phagosomes of various APCs (macrophages, dendritic cells, and microglials) more
efficiently than NPs prepared with an inert polymer PLGA. In chapter-IV, we have tested
the ability of InAc-NPs in delivering another TLR7 agonist, C-563 along with the antigen
to APCs to generate a strong immune response. InAc-NPs released encapsulated C-563 in
a sustained manner. Importantly, InAc-NPs containing C-563 activated murine
macrophages in both TLR4 and TLR7 dependent pathways. The C-563 containing InAc-
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NPs produced very strong antibody titers in mice and cytokines in ex-vivo cultures that
represent both humoral and cellular immunity. Importantly, such robust activity was
observed even without encapsulation of the antigen inside the particles, which was shown
for the first time for InAc particles. This is very significant in the translation of the
technology for the field application as encapsulation procedures usually lead to the loss
of significant antigen. Conserving antigen will be critical in pandemic attacks where there
is a severe shortage of antigens.
Further, InAc-563-based dual TLR4/7 system will be developed as a potential
novel synergistic vaccine adjuvant system for cancer immune therapy. InAc-NPs (a
TLR4 agonist) failed to stimulate a strong immune response when delivered orally (data
not shown here), may be due to gut tolerance developed to commonly encountered TLR4
ligands in the gut (LPS from E.coli or other microbes). However, with the development
of combination technology, InAc-NPs could be used as a delivery system for TLR7/8
agonists in the future oral vaccine development.
In conclusion, the dissertation advanced a new platform technology for mucosal
vaccines for both human and animal applications. In addition, a preliminary study was
performed to explore InAc-NPs as a delivery system for other TLR agonists, which could
have implications in oral vaccine delivery or dual adjuvant delivery for cancer immune
therapy.
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